WO1997047602A1 - Tricyclic amine derivatives - Google Patents

Tricyclic amine derivatives Download PDF

Info

Publication number
WO1997047602A1
WO1997047602A1 PCT/EP1997/002985 EP9702985W WO9747602A1 WO 1997047602 A1 WO1997047602 A1 WO 1997047602A1 EP 9702985 W EP9702985 W EP 9702985W WO 9747602 A1 WO9747602 A1 WO 9747602A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
butyl
compound
phenylbenzoylamino
octahydrobenzo
Prior art date
Application number
PCT/EP1997/002985
Other languages
French (fr)
Inventor
Geoffrey Stemp
Christopher Norbert Johnson
Stephen Allan Smith
Phillip Jeffrey
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to US09/202,335 priority Critical patent/US6080752A/en
Priority to EP97928161A priority patent/EP0906284A1/en
Priority to JP10501180A priority patent/JP2000511917A/en
Publication of WO1997047602A1 publication Critical patent/WO1997047602A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles

Definitions

  • the present invention relates to novel tricyclic amine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, in particular as antipsychotic agents.
  • R* represents a group of formula (A) or (B):
  • R ⁇ represents a hydrogen atom or a C1.4a.kyl group
  • R 3 represents a substituent selected from: a hydrogen or halogen atom, a hydroxy, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, C1.4a.kyl, C ⁇ _4alkoxy, arylC ⁇ _4alkoxy, C ⁇ _4alkylthio, C ⁇ _4alkoxyC ⁇ _4alkyl, C3_6cycloalkylC ⁇ _ 4alkoxy, C ⁇ _4alkanoyl, C ⁇ _4alkoxycarbonyl, C ⁇ _4alkylsulphonyl, C ⁇ _4alkylsulphonyloxy, C1_4alkylsulphonylC1.4a.kyl, arylsulphonyl, arylsulphonyloxy or arylsulphonylC ⁇ _4alkyl group, a group R 3 OCO(CH2) p , R 3 R 4 NCO(CH2> p or
  • T represents CH2, CH2CH2 or OCH2;
  • V represents CH2, O or a bond
  • Ar and Ar* each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring;
  • Y represents a bond, -NHCO-, -CONH-, -CH2-, or -(CH2) m Y 1 (CH2) n -, wherein Y* represents O, S, SO2, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1 ; and salts thereof.
  • an alkyl group or moiety may be straight or branched.
  • Alkyl groups which may be employed include methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec- pentyl, and the like.
  • R 3 represents an arylCi ⁇ alkoxy, arylsulphonyl, arylsulphonyloxy or arylsulphonylC ⁇ .4alkyl group
  • the aryl moiety may be selected from an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered heterocyclic ring.
  • a halogen atom present in the compounds of formula (I) may be fluorine, chlorine, bromine or iodine.
  • the substituents R 3 may be the same or different.
  • q represents 1.
  • Ar represents an optionally substituted phenyl group this may carry one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, cyano, nitro, C ⁇ _4alkyl, C ⁇ _4alkoxy C ⁇ _4alkanoyl or C ⁇ _4alkylsulphonyl group.
  • An optionally substituted 5- or 6-membered heterocyclic aromatic ring as defined for either of the groups Ar, Ar* or Ar ⁇ may contain from 1 to 4 heteroatoms selected from O, N or S. When the ring contains 2-4 heteroatoms, one is preferably selected from O, N and S and the remaining heteroatoms are preferably N.
  • 5 and 6- membered heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl and pyrazolyl.
  • the heterocyclic ring may be optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, cyano, nitro, C ⁇ _4alkyl, C ⁇ _4alkoxy C ⁇ _4alkanoyl or C ⁇ _4alkylsulphonyl group.
  • salts of formula (I) should be physiologically acceptable.
  • suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids eg. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids eg. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulphonic, methanesulphonic or naphthalenesulphonic acid.
  • Other non-physiologically acceptable salts eg. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.
  • the compounds of formula (I) contain two or more asymmetric centres.
  • Such compounds can exist in diastereomeric forms.namely cis and trans isomers; both forms and all mixtures thereof are included within the scope of this invention.
  • each diastereoisomer can exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention.
  • (+) and (-) designations used herein indicate the direction of rotation of plane-polarised light by the compounds.
  • the prefix (+) indicates that the isomer is dextrorotatory (which can also be designated d) and the prefix (-) indicates the levorotatory isomer (which can also be designated 1). It will thus be appreciated that the invention extends to the individual diastereoisomers, individual enantiomers and any and all mixtures of these forms.
  • Particular compounds according to the invention include : /ra/t5-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzoffjquinoline; ris-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; fr ⁇ «5-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzo[f]quinoline; cw-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; tr ⁇ S-7-methylsulf
  • the present invention also provides a process for preparing compounds of formula (I) which process comprises :
  • W is a halogen atom or a trifluoromethylsulphonyloxy group, or W is a group M selected from a boron derivative e.g. a boronic acid function B(OH)2 or a metal function such as trialkylstannyl e.g. SnBu3, zinc halide or magnesium halide; with a compound:
  • Process (a) requires the presence of a reducing agent.
  • Suitable reducing agents which may be employed include sodium borohydride, cyanoborohydride or triacetoxyborohydride under acidic conditions, or catalytic hydrogenation.
  • the reaction may conveniently be effected in a solvent such as ethanol.
  • the compound of formula (II) may be employed in this process as a mixture of cis and trans isomers, but more preferably the cis and trans isomers are separated prior to reaction with a compound (III).
  • R ⁇ represents a group of formula (A) and T represents CH2CH2
  • the compound of formula (II) is advantageously employed as the trans isomer.
  • Process (b) may be effected by methods well known in the art for formation of an amide bond.
  • Reaction of a compound of formula (VI) with Ar* W ⁇ may be effected in the presence of a transition metal eg palladium catalyst such as bis- triphenylphosphinepalladium dichloride or rerr ⁇ w-triphenylphosphinepalladium (0).
  • a transition metal eg palladium catalyst
  • M represents a boronic acid function such as B(OH) 2
  • the reaction may be carried out under basic conditions, for example using aqueous sodium carbonate in a suitable solvent such as dioxane.
  • M is trialkylstannyl
  • the reaction may be carried out in an inert solvent, such as xylene or dioxane optionally in the presence of LiCl.
  • M is a zinc or magnesium halide
  • the reaction may be effected in an aprotic solvent such as tetrahydrofuran.
  • the substituent W is preferably a halogen atom such as bromine, or a sulphonyloxy group such as trifluoromethylsulphonyloxy; and W* is preferably a goup M, such as trialkylstannyl or B(OH)2- Interconversion reactions according to process (d) may be effected using methods well known in the art.
  • a compound of formula (LV) may be prepared by alkylation of a compound (LI) by standard methods.
  • a compound of formula (II) may be reacted with N-(4-bromobutylphthalimide) followed by removal of the phthalimide group to give a compound of formula (IV) where R ⁇ is hydrogen.
  • Compounds where R ⁇ is alkyl may be prepared by subsequent reaction with the appropriate aldehyde using conditions analogous to process (a) above.
  • Compounds of formula (I) have been found to exhibit affinity for dopamine receptors, in particular the D3 receptor, and are expected to be useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. Compounds of formula (I) have also been found to have greater affinity for dopamine D3 than for D2 receptors.
  • antipsychotic agents neuropeptides
  • eps extrapyramidal side effects
  • Preferred compounds of the present invention are therefore those which have higher affinity for dopamine D3 than dopamine D2 receptors (such affinity can be measured using standard methodology for example using cloned dopamine receptors). Said compounds may advantageously be used as selective modulators of D3 receptors.
  • D3 antagonists are of potential use as antipsychotic agents for example in the treatment of schizophrenia, schizo-affective disorders, psychotic depression and mania.
  • Conditions which may be treated by dopamine D3 receptor agonists include dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; depression; anxiety, memory disorders, sexual dysfunction and drug (eg. cocaine) dependency.
  • the present invention provides a method of treating conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a physiologically acceptable salt thereof.
  • the invention also provides the use of a compound of formula (I) or a physiologically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia.
  • a preferred use for D3 antagonists according to the present invention is in the treatment of psychoses such as schizophrenia.
  • a preferred use for D3 agonists according to the present invention is in the treatment of dyskinetic disorders such as Parkinson's disease.
  • the compounds of the present invention are usually administered as a standard pharmaceutical composition.
  • the present invention therefore provides in a further aspect pharmaceutical compositions comprising a novel compound of formula (I) or a physiologically acceptable salt thereof and a physiologically acceptable carrier.
  • the compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
  • the compounds of formula (I) and their physiologically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
  • a liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
  • the formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
  • a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
  • suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
  • a composition in the form of a capsule can be prepared using routine encapsulation procedures.
  • pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
  • compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
  • the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
  • Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
  • Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non- aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device.
  • the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted.
  • the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluoro- chlorohydrocarbon.
  • the aerosol dosage forms can also take the form of a pump- atomiser.
  • compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
  • compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
  • compositions suitable for transdermal administration include ointments, gels and patches.
  • the composition is in unit dose form such as a tablet, capsule or ampoule.
  • Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base.
  • the physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 10 mg and 400 mg.e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
  • the compounds will be administered for a period of continuous therapy, for example for a week or more.
  • the ability of the compounds to bind selectively to human D3 dopamine receptors can be demonstrated by measuring their binding to cloned receptors.
  • the inhibition constants (Kj) of test compounds for displacement of [ ⁇ F] iodosulpride binding to human D3 dopamine receptors expressed in CHO cells were determined as follows. The cell lines were shown to be free from bacterial, fungal and mycoplasmal contaminants, and stocks of each were stored frozen in liquid nitrogen. Cultures were grown as monolayers or in suspension in standard cell culture media. Cells were recovered by scraping (from monolayers) or by centrifugation (from suspension cultures), and were washed two or three times by suspension in phosphate buffered saline followed by collection by centrifugation. Cell pellets were stored frozen at -40°C. Crude cell membranes were prepared by homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding.
  • the membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), using an Ultra-Turrax, and recentrifuged at 18,000 r.p.m for 15 min at 4°C in a Sorvall RC5C. The membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 @ 37°C). The final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C), and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254).
  • the functional activity of compounds at human D2 and human D3 receptors may be determined using a Cytosensor Microphysiometer (McConnell HM. et. al., Science, 1992, 257, 1906-1912).
  • McConnell HM. et. al. Science, 1992, 257, 1906-1912.
  • cells hD2_CHO or hD3_CHO were seeded into 12mm Transwell inserts (Costar) at 300000 cells/cup in foetal calf serum (FCS)-containing medium. The cells were incubated for 6h at 37°C in 5%CO2, before changing to FCS-free medium.
  • cups were loaded into the sensor chambers of the Cytosensor Microphysiometer (Molecular Devices) and the chambers perfused with running medium (bicarbonate-free Dulbecco's modified Eagles medium containing 2 mM glutamine and 44 mM NaCI) at a flow rate of 100 ul/min. Each pump cycle lasted 90s. The pump was on for the first 60s and the acidification rate determined between 68 and 88s, using the Cytosoft programme. Test compounds were diluted in running medium. In experiments to determine agonist activity, cells were exposed (4.5 min for hD2, 7.5 min for hD3) to increasing concentrations of putative agonist at half hour intervals. Seven concentrations of the putative agonist were used.
  • running medium bicarbonate-free Dulbecco's modified Eagles medium containing 2 mM glutamine and 44 mM NaCI
  • Buffer Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
  • Solvent Typically water but may also include cyclodextrins (1-100 mg) and co- solvents such as propylene glycol, polyethylene glycol and alcohol. Tablet
  • Diluent e.g. Microcrystalline cellulose, lactose, starch
  • Binder e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
  • Disintegrant e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
  • Suspending agent e.g. Xanthan gum, microcrystalline cellulose
  • Diluent e.g. sorbitol solution, typically water
  • Preservative e.g. sodium benzoate
  • Buffer e.g. citrate
  • Co- solvent e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
  • Acetic acid (12.5ml) was added to a stirred mixture of 2-oxo- 1,2,3,4- tetrahydronaphthalene-3-acetic acid methyl ester (3.62g, 17mmol), and benzylamine (7.2ml, 66mmol) in a 1:1 mixture of tetrahydrofuran and methanol (120ml) at 0°C under argon.
  • sodium cyanoborohydride (2.09g, 33mmol) was added and the resultant mixture stirred at room temperature.
  • aqueous 10% sodium hdyroxide was added and the solvent evaporated in vacuo. The residue was partitioned between water (100ml) and dichloromethane (2x200ml).
  • Methanesulfonyl chloride (0.04ml, 0.5mmol) was added to a stirred solution of trans-1- hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline(E3, 200mg, 0.4mmol) and triethylamine (0.07ml, 0.5mmol) in dichloromethane (5ml) at room temperature. The mixture was stirred for 12h and then poured onto saturated aqueous K j CO, (10ml) and extracted onto dichloromethane (3x10ml).
  • Methanesulfonyl chloride (0.04ml, 0.5mmol) was added to stirred solution of ⁇ s-7- hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzoffjquinoline (E4, 200mg, 0.4mmol) and triethylamine (0.07ml, 0.5mmol) in dichloromethane (5ml) at room temperature. The mixture was stirred for 2h and then poured onto saturated aqueous K j CO, (10ml) and extracted into dichloromethane (3x10ml).
  • Example 10 cis-23 » 3a,4,9,9a-Hexahydro-5-methoxy-l-(4-(4-phenylbenzoy!amino)butyl)-Lff- benz[f]indole hydrochloride
  • 4-(4-phenylbenzoylamino)butyraldehyde 0.1 lg, 0.40mmol
  • sodium triacetoxyborohydride (0.13g, 0.6 lmmol

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) wherein R1 represents a group of formula (A) or (B); R2 represents a hydrogen atom or a C¿1-4?alkyl group; R?3¿ represents a substituent selected from: a hydrogen or halogen atom, a hydroxy, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, C¿1-4?alkyl, C1-4alkoxy, arylC1-4alkoxy, C1-4alkylthio, C1-4alkoxyC1-4alkyl, C3-6cycloalkylC1-4alkoxy, C1-4alkanoyl, C1-4alkoxycarbonyl, C1-4alkylsulphonyl, C1-4alkylsulphonyloxy, C1-4alkylsulphonylC1-4alkyl, arylsulphonyl, arylsulphonyloxy or arylsulphonylC1-4alkyl group, a group R?3¿OCO(CH¿2?)p, R?3R4¿NCO(CH¿2?)p or R?3R4NSO¿2(CH2)p where each of R?3 and R4¿ independently represents a hydrogen atom or a C¿1-4?alkyl group and p represents zero or an integer from 1 to 4, or a group Ar?2¿-Z, wherein Ar2 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring and Z represents a bond, O, S, or CH¿2?; q is 1 or 2; T represents CH2, CH2CH2 or OCH2; V represents CH2, O or a bond; Ar and Ar?1¿ each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; and Y represents a bond, -NHCO-, -CONH-, -CH¿2?-, or -(CH2)mY?1(CH¿2)n-, wherein Y1 represents O, S, SO¿2?, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1; and salts thereof have activity at dopamine receptors and are useful in the treatment of psychoses such as schizophrenia.

Description

TRICYCLIC AMINE DERIVATIVES
The present invention relates to novel tricyclic amine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, in particular as antipsychotic agents.
We have now found a class of tricyclic amine derivatives which have affinity for dopamine receptors, in particular the D3 receptor, and thus potential in the treatment of conditions wherein modulation of the D3 receptor is beneficial, eg as antipsychotic agents.
In a first aspect the present invention provides compounds of formula (I) :
Figure imgf000003_0001
Formula (I)
wherein R* represents a group of formula (A) or (B):
Figure imgf000003_0002
R^ represents a hydrogen atom or a C1.4a.kyl group;
R3 represents a substituent selected from: a hydrogen or halogen atom, a hydroxy, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, C1.4a.kyl, Cι_4alkoxy, arylCι_4alkoxy, Cι_4alkylthio, Cι_4alkoxyCι_4alkyl, C3_6cycloalkylCι_ 4alkoxy, Cι_4alkanoyl, Cι_4alkoxycarbonyl, Cι_4alkylsulphonyl, Cι_4alkylsulphonyloxy, C1_4alkylsulphonylC1.4a.kyl, arylsulphonyl, arylsulphonyloxy or arylsulphonylCι_4alkyl group, a group R3OCO(CH2)p, R3R4NCO(CH2>p or R3R^NSO2(CH2)p where each of R3 and R4 independently represents a hydrogen atom or a Cι_4alkyl group and p represents zero or an integer from 1 to 4, or a group Ar^-Z, wherein Ar^ represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring and Z represents a bond, O, S , or CH2; q is 1 or 2;
T represents CH2, CH2CH2 or OCH2;
V represents CH2, O or a bond;
Ar and Ar* each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and
Y represents a bond, -NHCO-, -CONH-, -CH2-, or -(CH2)mY1(CH2)n-, wherein Y* represents O, S, SO2, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1 ; and salts thereof. In the compounds of formula (I) above an alkyl group or moiety may be straight or branched. Alkyl groups which may be employed include methyl, ethyl, n-propyl, n- butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec- pentyl, and the like.
When R3 represents an arylCi^alkoxy, arylsulphonyl, arylsulphonyloxy or arylsulphonylCι.4alkyl group, the aryl moiety may be selected from an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered heterocyclic ring.
A halogen atom present in the compounds of formula (I) may be fluorine, chlorine, bromine or iodine.
When q is 2, the substituents R3 may be the same or different. Preferably q represents 1.
When Ar, Ar* or Ar^ represents an optionally substituted phenyl group this may carry one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, cyano, nitro, Cι_4alkyl, Cι_4alkoxy Cι_4alkanoyl or Cι_4alkylsulphonyl group.
An optionally substituted 5- or 6-membered heterocyclic aromatic ring, as defined for either of the groups Ar, Ar* or Ar^ may contain from 1 to 4 heteroatoms selected from O, N or S. When the ring contains 2-4 heteroatoms, one is preferably selected from O, N and S and the remaining heteroatoms are preferably N. Examples of 5 and 6- membered heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl and pyrazolyl. The heterocyclic ring may be optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, cyano, nitro, Cι_4alkyl, Cι_4alkoxy Cι_4alkanoyl or Cι_4alkylsulphonyl group.
It will be appreciated that for use in medicine the salts of formula (I) should be physiologically acceptable. Suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids eg. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids eg. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulphonic, methanesulphonic or naphthalenesulphonic acid. Other non-physiologically acceptable salts eg. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I). It will be appreciated that the compounds of formula (I) contain two or more asymmetric centres. Such compounds can exist in diastereomeric forms.namely cis and trans isomers; both forms and all mixtures thereof are included within the scope of this invention. Furthermore, each diastereoisomer can exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of the two are included within the scope of the invention. In accordance with convention the (+) and (-) designations used herein indicate the direction of rotation of plane-polarised light by the compounds. The prefix (+) indicates that the isomer is dextrorotatory (which can also be designated d) and the prefix (-) indicates the levorotatory isomer (which can also be designated 1). It will thus be appreciated that the invention extends to the individual diastereoisomers, individual enantiomers and any and all mixtures of these forms.
Particular compounds according to the invention include : /ra/t5-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzoffjquinoline; ris-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; frα«5-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzo[f]quinoline; cw-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; trαΛS-7-methylsulfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6, 1 Ob¬ oe tahydrobenzo[f]quinoline; cw-7-methylsulfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; /rα/w-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; cw-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline; c«-2,3,3a,4,9,9a-hexahydro-l-(4-(4-phenylbenzoylamino)butyl)-lH-benz[f]indole; cw-2,3,3a,4,9,9a-hexahydro-5-methoxy-l-(4-(4-phenylbenzoylamino)butyl)-lH- benz[f]indole; irfl/ty-8-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; rrα/w-2,3,3a,4,5,9b-hexahydro-3-(4-(4-phenylbenzoylamino)butyl)-lH-benz[e]indole; rrα/tϊ-2,3,3a,4,5,9b-hexahydro-6-methoxy-3-(4-(4-phenylbenzoylamino)butyl-lH- benz[e]indole; (4aS, 10bS)-rrαΛy-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l ,2,3,4,4a,5,6, 10b- octahydrobenzo[f]quinoline; rrflrU-8-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4 ,4a,5,6, 10b- octahydrobenzo[f]quinoline; ϊrαfu-2,3,3a,4,5,9b-hexahydro-6-hydroxy-3-(4-(4-phenylbenzoylamino)butyl)-lH- benz[e]indole; (4a5, 10b5)-rrfl/t5-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzoff] quinoline; /rflΛS-2,3,3a,4,5,9b-hexahydro-6-methylsulfonyloxy-3-(4-(4-phenylbenzoylamino)butyl)- lH-benz[e]indole; (4aS, 10b5)-frαrtϊ-7-methylsulfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline; and salts thereof.
The present invention also provides a process for preparing compounds of formula (I) which process comprises :
(a) reacting a compound of formula (II):
R!H Formula (II)
wherein R1 is as hereinbefore defined; with a compound of formula (III):
Figure imgf000006_0001
Formula (III)
wherein R^, Y, Ar and Ar^ are as hereinbefore defined;
(b) reaction of a compound of formula (IV):
Figure imgf000007_0001
Formula (IV)
wherein R* and R^ are as hereinbefore defined; with a compound of formula (V):
Arl-Y-ArCOX
Formula (V)
wherein Y, Ar and Ar^ are as hereinbefore defined and X is a halogen atom or the residue of an activated ester; (c) to prepare a compound of formula (I) where Y is a bond, reaction of a compound of formula (VI):
Figure imgf000007_0002
Formula (VI)
wherein R1, R^ and Ar are as hereinbefore defined, and W is a halogen atom or a trifluoromethylsulphonyloxy group, or W is a group M selected from a boron derivative e.g. a boronic acid function B(OH)2 or a metal function such as trialkylstannyl e.g. SnBu3, zinc halide or magnesium halide; with a compound:
Ari-W1 wherein W* is a halogen atom or a trifluoromethylsulphonyloxy group when W is a group M, or W* is a group M when W is a halogen atom or a trifluoromethylsulphonyloxy group. (d) interconversion of one compound of formula (I) to a different compound of formula (I) e.g. (i) alkylation of a compound (I) wherein R^ represents hydrogen, (ii) conversion of one R3 from alkoxy (e.g.methoxy) to hydroxy, or (iii) conversion of R3 from hydroxy to sulphonyloxy, eg alkylsulphonyloxy or trifluoromethanesulphonyloxy; (iv) conversion of a compound wherein Y represents S to a compound wherein Y is SO2 or (v) conversion of Y from CO to CH2; and optionally thereafter forming a salt of formula (I).
Process (a) requires the presence of a reducing agent. Suitable reducing agents which may be employed include sodium borohydride, cyanoborohydride or triacetoxyborohydride under acidic conditions, or catalytic hydrogenation. The reaction may conveniently be effected in a solvent such as ethanol. The compound of formula (II) may be employed in this process as a mixture of cis and trans isomers, but more preferably the cis and trans isomers are separated prior to reaction with a compound (III). When R^ represents a group of formula (A) and T represents CH2CH2 the compound of formula (II) is advantageously employed as the trans isomer.
Process (b) may be effected by methods well known in the art for formation of an amide bond.
Reaction of a compound of formula (VI) with Ar* W^ , according to process (c) may be effected in the presence of a transition metal eg palladium catalyst such as bis- triphenylphosphinepalladium dichloride or rerrαΛw-triphenylphosphinepalladium (0). When M represents a boronic acid function such as B(OH)2the reaction may be carried out under basic conditions, for example using aqueous sodium carbonate in a suitable solvent such as dioxane. When M is trialkylstannyl the reaction may be carried out in an inert solvent, such as xylene or dioxane optionally in the presence of LiCl. When M is a zinc or magnesium halide the reaction may be effected in an aprotic solvent such as tetrahydrofuran. The substituent W is preferably a halogen atom such as bromine, or a sulphonyloxy group such as trifluoromethylsulphonyloxy; and W* is preferably a goup M, such as trialkylstannyl or B(OH)2- Interconversion reactions according to process (d) may be effected using methods well known in the art.
Compounds of formula (LI) wherein R* represents a group of formula (A) and T represents CH2CH2 may be prepared for example according to the following reaction scheme (I) (see also Cannon, J.G.; et al., J. Med. Chem., 1976 (19) 987-993):
Scheme I
Figure imgf000009_0001
(b)
Figure imgf000009_0002
isomers
(I) cis
Formula (IIA) separate cis and trans isomers
Reaction conditions:
(a) solvent such as benzene, under reflux conditions with p-toluenesulphonic acid in catalytic quantity; (b) (i) cyclisauon, e.g. by heating with acrylamide at elevated temperature (>502C).
(ii) product of (b)(i) reacted with a methylating agent such as iodomethane in a solvent such as dimethoxyethane in the presence of a base such as sodium hydride.
(c) (i) reduction of the oxo function, using a reducing agent such as sodium bis-(2- methoxyethoxy) aluminium hydride in toluene (Red-Al).
(ii) reduction of the double bond using a reducing agent such as sodium borohydride in a solvent such as methanol. This step results in a mixture of cis and trans isomers, which may be separated at this stage, or following demethylation.
(d) demethylation using standard methods e.g. reaction with 1- chloroethylch.oroformate.
(e) separation of cis and trans isomers by conventional methods e.g. chromatography.
Alternatively compounds of formula (II) wherein R* is a group (A) and T is CH2CH2 may be obtained as the trans isomers according to the following reaction scheme (II):
Scheme π
Figure imgf000011_0001
(b)
Figure imgf000011_0002
Figure imgf000011_0003
trans
(d)
Figure imgf000011_0004
Formula IIA trans trans
Reaction Conditions
(a) formation of aziridine ring e.g. using Phi = NTs in the presence of a copper catalyst such as Cu(II)acetylacetonate (Cu(acac)2 ) or Cu(II)triflate (Cu(OTF)2 ). Alternatively a chiral catalyst may be employed (see D.A. Evans et al., J. Am. Chem. Soc., 1993, 115, 5328 and E.N. Jacobsen et al., J. Am. Chem. Soc., 1993, 115, 5326). The single enantiomers of the aziridines produced by the methodology described in the above references can be converted to the corresponding enantiomers of the amines of Formula (HA) by the process described in Scheme II.
(b) ring opening using a Grignard reagent, e.g. allyl magnesium bromide in a solvent such as diethyl ether.
(c) (i) hydroboration of the double bond using e.g. borane in a solvent such as tetrahydrofuran, followed by oxidation, using e.g. hydrogen peroxide.
(d) (i) conversion of the hydroxy function to a leaving group using e.g. methanesulphonyl chloride or p-toluenesulphonyl chloride, followed by
(ii) cyclisation under basic conditions (e.g. potassium carbonate).
(e) cleavage of the N-tosyl group by reductive methods e.g. using lithium aluminium hydride, or Red-Al.
When Rl is a group (B) and T represents CH2, compounds of formula (II) may be prepared by the procedure described by C-H Lin et al., J. Med. Chem., 1993, 36, 1069-1083, according to Scheme (in):
Scheme ID
Figure imgf000013_0001
(b)
Figure imgf000013_0002
(f)
Figure imgf000013_0003
Formula (LIB)
Reaction Conditions:
(a) Insertion of 2-propenyl function by the following steps:
(i) Lithium diisopropylamide, (MeO)2CO, tetrahydrofuran;
(ii) Lithium diisopropylamide, allyl bromide, tetrahydrofuran; (iii) Lithium chloride in dimethylsulphoxide or sodium chloride in dimethylformamide.
(b) formation of ketal by reaction with trimethyl orthoformate, ethanediol and p- toluenesulphonic acid in dichloromethane,
(c) oxidative cleavage of double bond with formation of carboxylate function followed by acetal cleavage by reaction with
(i) potassium permanganate and sodium periodate in water,
(ii) acetonitrile and methanolic hydrochloric acid.
(d) cyclisation by reaction with amine under reductive conditions e.g. benzylamine, acetic acid, sodium cyanoborohydride.
(e) reduction of oxo function using e.g. lithium aluminium hydride in tetrahydrofuran.
(f) cleavage of N-protecting group (benzyl) by standard methods e.g. catalytic hydrogenation using e.g. palladium hydroxide or by reaction with
1 -chloroethylchloroformate.
Compounds of formula (III) are known or may be prepared using standard procedures.
A compound of formula (LV) may be prepared by alkylation of a compound (LI) by standard methods. Thus, for example a compound of formula (II) may be reacted with N-(4-bromobutylphthalimide) followed by removal of the phthalimide group to give a compound of formula (IV) where R^ is hydrogen. Compounds where R^ is alkyl may be prepared by subsequent reaction with the appropriate aldehyde using conditions analogous to process (a) above.
Compounds of formula (VI) may be prepared by processes analogous to (a) or (b) described above. Compounds Ar^W^ are commercially available or may be prepared by standard methods. It will be appreciated that compounds of formula (IV) or formula (VI) may be prepared as in the form of cis or trans isomers, or mixtures thereof, starting with the appropriate isomer of formula (II).
Compounds of formula (I) have been found to exhibit affinity for dopamine receptors, in particular the D3 receptor, and are expected to be useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. Compounds of formula (I) have also been found to have greater affinity for dopamine D3 than for D2 receptors. The therapeutic effect of currently available antipsychotic agents (neuroleptics) is generally believed to be exerted via blockade of D2 receptors; however this mechanism is also thought to be responsible for undesirable extrapyramidal side effects (eps) associated with many neuroleptic agents. Without wishing to be bound by theory, it has been suggested that blockade of the recently characterised dopamine D3 receptor may give rise to beneficial antipsychotic activity without significant eps. (see for example Sokoloff et al, Nature, 1990; 347: 146-151; and Schwartz et al, Clinical Neuropharmacology, Vol 16, No. 4, 295-314, 1993). Preferred compounds of the present invention are therefore those which have higher affinity for dopamine D3 than dopamine D2 receptors (such affinity can be measured using standard methodology for example using cloned dopamine receptors). Said compounds may advantageously be used as selective modulators of D3 receptors. We have found that certain compounds of formula (I) are dopamine D3 receptor antagonists, others may be agonists or partial agonists. The functional activity of compounds of the invention (i.e. whether they are antagonists, agonists or partial agonists) can be readily determined using the test method described hereinafter, which does not require undue experimentation. D3 antagonists are of potential use as antipsychotic agents for example in the treatment of schizophrenia, schizo-affective disorders, psychotic depression and mania. Conditions which may be treated by dopamine D3 receptor agonists include dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; depression; anxiety, memory disorders, sexual dysfunction and drug (eg. cocaine) dependency. In a further aspect therefore the present invention provides a method of treating conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) or a physiologically acceptable salt thereof. The invention also provides the use of a compound of formula (I) or a physiologically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which require modulation of dopamine D3 receptors, for example psychoses such as schizophrenia.
A preferred use for D3 antagonists according to the present invention is in the treatment of psychoses such as schizophrenia. A preferred use for D3 agonists according to the present invention is in the treatment of dyskinetic disorders such as Parkinson's disease.
For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical compositions comprising a novel compound of formula (I) or a physiologically acceptable salt thereof and a physiologically acceptable carrier.
The compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly. The compounds of formula (I) and their physiologically acceptable salts which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration. Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non- aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluoro- chlorohydrocarbon. The aerosol dosage forms can also take the form of a pump- atomiser.
Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
Compositions suitable for transdermal administration include ointments, gels and patches. Preferably the composition is in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base. The physiologically acceptable compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 500 mg, preferably between 10 mg and 400 mg.e.g. between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, e.g. between 1 and 25 mg of the compound of the formula (I) or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more. Biological Test Methods
The ability of the compounds to bind selectively to human D3 dopamine receptors can be demonstrated by measuring their binding to cloned receptors. The inhibition constants (Kj) of test compounds for displacement of [^F] iodosulpride binding to human D3 dopamine receptors expressed in CHO cells were determined as follows. The cell lines were shown to be free from bacterial, fungal and mycoplasmal contaminants, and stocks of each were stored frozen in liquid nitrogen. Cultures were grown as monolayers or in suspension in standard cell culture media. Cells were recovered by scraping (from monolayers) or by centrifugation (from suspension cultures), and were washed two or three times by suspension in phosphate buffered saline followed by collection by centrifugation. Cell pellets were stored frozen at -40°C. Crude cell membranes were prepared by homogenisation followed by high-speed centrifugation, and characterisation of cloned receptors achieved by radioligand binding.
Preparation of CHO cell membranes
Cell pellets were gently thawed at room temperature, and resuspended in about 20 volumes of ice-cold 50 mM Tris salts (pH 7.4 <α> 37°C), 20mM EDTA, 0.2 M sucrose. The suspension was homogenised using an Ultra-Turrax at full speed for 15 sec. The homogenate was centrifuged at 18,000 r.p.m for 20 min at 4°C in a Sorvall RC5C centrifuge. The membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C), using an Ultra-Turrax, and recentrifuged at 18,000 r.p.m for 15 min at 4°C in a Sorvall RC5C. The membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 @ 37°C). The final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C), and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254).
Binding experiments on cloned dopamine receptors
Crude cell membranes were incubated with 0.1 nM [1^1] iodosulpride (~2000 Ci/mmol; Amersham, U. K.), and the test compound in a buffer containing 50 mM Tris salts (pH 7.4 @ 37°C), 120 mM NaCI, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 0.1% (w/v) bovine serum albumin, in a total volume of 1 ml for 30 min at 37°C. Following incubation, samples were filtered using a Brandel Cell Harvester, and washed three times with ice- cold 50 mM Tris salts (pH 7.4 @ 37°C), 120 mM NaCI, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2- The radioactivity on the filters was measured using a Cobra gamma counter (Canberra Packard). Non-specific binding was defined as the radioligand binding remaining after incubation in the presence of 100 μM iodosulpride. For competition curves, 14 concentrations (half-log dilutions) of competing cold drug were used. Competition curves were analysed simultaneously whenever possible using non-linear least-squares fitting procedures, capable of fitting one, two or three site models.
Compounds of Examples tested according to this method had pKi values in the range 6.5 - 9.0 at the human dopamine D3 receptor.
Functional Activity at cloned dopamine receptors
The functional activity of compounds at human D2 and human D3 receptors (ie agonism or antagonism) may be determined using a Cytosensor Microphysiometer (McConnell HM. et. al., Science, 1992, 257, 1906-1912). In Microphysiometer experiments, cells (hD2_CHO or hD3_CHO) were seeded into 12mm Transwell inserts (Costar) at 300000 cells/cup in foetal calf serum (FCS)-containing medium. The cells were incubated for 6h at 37°C in 5%CO2, before changing to FCS-free medium. After a further 16-18h, cups were loaded into the sensor chambers of the Cytosensor Microphysiometer (Molecular Devices) and the chambers perfused with running medium (bicarbonate-free Dulbecco's modified Eagles medium containing 2 mM glutamine and 44 mM NaCI) at a flow rate of 100 ul/min. Each pump cycle lasted 90s. The pump was on for the first 60s and the acidification rate determined between 68 and 88s, using the Cytosoft programme. Test compounds were diluted in running medium. In experiments to determine agonist activity, cells were exposed (4.5 min for hD2, 7.5 min for hD3) to increasing concentrations of putative agonist at half hour intervals. Seven concentrations of the putative agonist were used. Peak acidification rate to each agonist concentration was determined and concentration-response curves fitted using Robofit [Tilford, N.S., Bowen, W.P. & Baxter, G.S. Br. J. Pharmacol. (1995) in press]. In experiments to determine antagonist potency, cells were treated at 30 min intervals with five pulses of a submaximal concentration of quinpirole (100 nM for hD2 cells, 30 nM for hD3 cells), before exposure to the lowest concentration of putative antagonist. At the end of the next 30 min interval, cells were pulsed again with quinpirole (in the continued presence of the antagonist) before exposure to the next highest antagonist concentration. In all, five concentrations of antagonist were used in each experiment. Peak acidification rate to each agonist concentration was determined and concentration-inhibition curves fitted using Robofit. Pharmaceutical Formulations
The following represent typical pharmaceutical formulations according to the present invention, which may be prepared using standard methods.
IV Infusion
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Solvent/complexing agent to 100 ml
Bolus Injection
Compound of formula (I) 1-40 mg
Buffer to pH ca 7
Co-Solvent to 5 ml
Buffer : Suitable buffers include citrate, phosphate, sodium hydroxide/hydrochloric acid.
Solvent : Typically water but may also include cyclodextrins (1-100 mg) and co- solvents such as propylene glycol, polyethylene glycol and alcohol. Tablet
Compound 1 - 40 mg
Diluent/Filler * 50 - 250 mg
Binder 5 - 25 mg
Disentegrant * 5 - 50 mg Lubricant 1 - 5 mg
Cyclodextrin 1 - 100 mg
* may also include cyclodextrins
Diluent : e.g. Microcrystalline cellulose, lactose, starch
Binder : e.g. Polyvinylpyrrolidone, hydroxypropymethylcellulose
Disintegrant : e.g. Sodium starch glycollate, crospovidone Lubricant : e.g. Magnesium stearate, sodium stearyl fumarate. Oral Suspension
Compound 1 - 40 mg
Suspending Agent 0.1 - 10 mg
Diluent 20 - 60 mg
Preservative 0.01 - 1.0 mg
Buffer to pH ca 5 - 8
Co-solvent 0 - 40 mg
Flavour 0.01 - 1.0 mg
Colourant 0.001 - 0.1 mg
Suspending agent :e.g. Xanthan gum, microcrystalline cellulose
Diluent : e.g. sorbitol solution, typically water Preservative : e.g. sodium benzoate Buffer : e.g. citrate Co- solvent : e.g. alcohol, propylene glycol, polyethylene glycol, cyclodextrin
The invention is further illustrated by the following non-limiting examples
Description 1 l-(5-Methoxy-3,4-dihydronaphthalen-2-yl)-pyrrolidine
A mixture of 5-methoxy-2-tetralone (lOOg, 0.68mmol), pyrrolidine (85.7ml, 1.03mol) and p-toluenesulfonic acid (lOOmg, catalytic) in benzene (1.2L) was heated at reflux under Dean-Stark conditions for 4h. The mixture was cooled and the solvent evaporated to give the title compound as a brown oil (155g, 99%). Mass spectrum (APO: 230 (MH+, 100%) CJSH„NO requires 299. Η NMR (CDCl,) δ: 1.90 (4H, m), 2.45 (2H, t, J = 7Hz), 2.84 (2H, t, J = 7Hz), 3.28 (4H, m), 3.80 (3H, s), 5.10 (IH, s), 6.48 (IH, d, J = 13Hz), 6.53 (IH, d, J = 13Hz), 7.0 (IH, m, J = 7Hz).
The following compound was prepared in a similar manner to description I
(a) l-(6-Methoxy-3,4-dihydronaphthalen-2-yl)-pyrrolidine
Η NMR (CDCl.) δ: 1.91 (4H, m), 2.46 (2H, t, J = 8 Hz), 2.81 (2H, t, J = 8 Hz), 3.24 (4H, m), 3.77 (3H, s), 5.12 (IH, s), 6.63 (2H, m), 6.78 (IH, m).
Description 2 7-Methoxy-l,4,5,6-tetrahydro-2H-benzo[f]quinolin-3-one
A mixture of acrylamide (146g, 2.0mol) and l-(5-methoxy-3,4-dihydronaphthalen-2- yOpyπolidine (156g, 0.68mol) was heated at 80°C for 2h and then 130°C for a further 0.75h. The mixture was cooled and water (IL) was added. The resultant brown precipitate was collected by filtration, washed with water and dried in vacuo. Trituration with hot ethanol (2L) gave the title compound as a white solid (35.9g, 23%). Mass spectrum (API*): 230 (MH*, 100%) C14H,5NO2 requires 229. Η NMR (CDC13) δ: 2.35 (2H, bt, J = 8Hz), 2.7 (4H, m), 2.92 (2H, t, J = 8Hz), 3.85 (3H, s), 6.75 (2H, m, J = 8Hz), 7.18 (IH, m, J = 8Hz), 7.9 (IH, br s).
The following compound was prepared in a similar manner to description 2
(a) 8-Methoxy-l,4,5,6-tetrahydro-2H-benzo[f]quinoIin-3-one 'H NMR (CDCl,) δ: 2.37 (2H, t, J = 8 Hz), 2.67 (4H, m), 2.99 (2H, t, J = 8 Hz), 3.80 (3H, s), 6.74 (2H, m), 7.04 (IH, d, J = 9 Hz), 8.00 (IH, br s).
Description 3 7-Methoxy-4-methyl-l,4 ,6-tetrahydro-2H-benzo[f]quinoIine-3-one
A mixture of 7-methoxy-l,4,5,6-tetrahydro-2H-benzoquinolin-3-one (20g, 87mmol) and sodium hydride (80% dispersion in oil, 2.9g, 96mmol) in anhydrous dimethoxyethane (300ml) was heated at reflux, under argon for 3h. The mixture was cooled, iodomethane (21.7ml, 349mmoI) added and the mixture refluxed for a further 4.5h. The mixture was cooled and water (10ml) was added dropwise with ice cooling. The resultant mixture was concentrated and the residue partitioned between water (50ml) and dichloromethane (3x50ml). The combined organic extracts were dried (NajSOJ and evaporated in vacuo to give the title compound as a solid (19.6g, 92%). Mass spectrum (API*): 244 (MH\ 100%) C15H17NO2 requires 243.
Η NMR (CDC13) δ: 2.25 (2H, t, J = 8Hz), 2.43 (4H, s), 2.71 (2H, t, J = 8Hz), 2.95 (3H, s), 3.65 (3H, s), 6.56 (2H, m, J = 8Hz), 6.98 (IH, m, J = 8Hz)
The following compound was prepared in a similar manner to description 3.
(a) 8-Methoxy-4-methyM,4,5,6-tetrahydro-2H-benzo[fJquinolin-3-one
Mass spectrum (API*): Found 244 (MH*). C15U„02 requires 243.
Description 4
7-Methoxy-4-methyJ-l,23,4,5,6-hexahydrobenzo[f]quinoline
A solution of sodium tøj-(2-methoxyethoxy)aluminium hydride in toluene (Red-Al, 65% wt, 37.2ml, 124mmol) was added to a stirred solution of 7-methoxy-4-methyl-l,4,5,6- tetrahydro-2H-benzo[f]quinoline-3-one (lOg, 41.2mmol) in toluene (200ml). The mixture was heated at reflux, under argon for 6h and allowed to cool. Water (7ml) was added dropwise with ice cooling and the aluminium salts dissolved by addition of 50% KOH (37ml). The organic phase was separated, washed with water (2x100ml), dried (Na.SOJ and concentrated in vacuo to afford an oil which was chromatographed on silica gel, with 10-15% ethyl acetate-pentane gradient elution to give the title compound as a yellow oil (5.5g, 58%) Mass spectrum (APT): 230 (MH*, 100%) CI3H19NO requires 229. 'H NMR (CDCl,) δ: 2.0 (2H, m), 2.35 (4H, m), 2.62 (3H, s), 2.80 (2H, t, J = 8Hz), 3.05 (2H, t, J = 8Hz), 3.81 (3H, s), 6.60 (IH, d, J = 9Hz), 6.68 (IH, d, J = 9Hz), 7.1 (IH, m, J = 8Hz).
The following compound was prepared in a similar manner to description 4.
(a) 8-Methoxy-4-methyl-l^,3,4,5,6-hexahydrobenzo[f]quinoline
Mass spectrum (API*): Found 230 (MH*).
Figure imgf000024_0001
requires 229.
Description 5 cis- and trans- 7-Methoxy-4-methyl-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Sodium borohydride (1.61g, 42mmol) was added portionwise over 5min to a stirring solution of 7-methoxy-4-methyl-l,2,3,4,5,6-hexahydrobenzo[fjquinoline (5.4g, 23mmol) in methanol (400ml). The mixture was stirred at room temperature under argon for 72h.
Acetic acid (10ml) was added dropwise and the mixture was concentrated in vacuo. The residue was basified with saturated NajCO,(50ml) and extracted into ether (3x30ml).
The combined organic extracts were washed with water, dried (Na.SO4) and the solvent evaporated to give the title compound as a yellow oil (4.5g, 84%).
Mass spectrum (API*): 232 (MH*, 100%) C^NO requires 231.
Η NMR (CDCl,) δ: 1.45 - 2.20 (6H, m), 2.30 - 2.67 (6H, m), 2.80 - 3.05 (3H, m), 3.80 and 3.82 (3H, 2xs), 6.65 - 7.13 (3H, m).
The following compound was prepared in a similar manner to description 5.
(a) cis and /rαns-(±)-8-Methoxy-4-methyl-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 232 (MH*). C^NO requires 231.
Description 6a
/rα/ιs-7-Methoxy-l,2,3,4,4a^,6,10b-octahydrobenzo[f]quinoline and
Description 6b cύ-7-Methoxy-l,2,3,4,4a5,6,10b-octahydrobenzo[f]quinoiine 1-Chloroethylchloroformate (4.62ml, 42.8mmol) was added with stirring to an ice cooled solution of cis- and trans- 7-methoxy-4-methyl-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline (4.3g, 18.6mmol) in dichloromethane (140ml). The mixture was allowed to warm to room temperature and stirred for a further 2h. Diisopropylethylamine (4.9ml, 28mmol) was added and the mixture heated at reflux for lh. The mixture was cooled and concentrated in vacuo before dissolving in methanol (100ml) and refluxing for lh. After cooling, the solvent was removed and the residue partitioned between saturated aqueous KjCO, (50ml) and dichloromethane (3x50ml). The combined organic extracts were washed with brine (50ml), dried (Na.SO4) and the solvent evaporated to afford a yellow oil. Chromatography on silica using 10% methanol-dichloromethane and 6.6ml/L 0.880 ammonia as eluent gave trans 7-methoxy- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (0.6g, 30%) as the first eluting isomer. Mass spectrum (API*): 218 (MH* 100%) CMHl9NO requires 217. Η NMR (CDCl,) δ: 1.48 - 2.25 (7H, m), 2.55 - 3.0 (5H, m), 3.15 - 3.25 (IH, m), 3.81 (3H, s), 6.68 (IH, d, J = 7Hz), 6.85 (IH, d, J = 7Hz), 7.15 (IH, t, J = 7Hz).
cw-7-Methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinoline (lg, 50%) was obtained as the second eluting isomer.
Mass spectrum (API*): 218 (MH*, 100%) CuH19NO requires 217. 'H NMR (CDCl,) δ: 1.40 - 1.85 (4H, m), 2.20 - 2.61 (7H, m), 2.68 - 2.85 (IH, m), 2.90 - 3.05 (IH, m), 3.61 (3H, s), 6.5 (IH, d, J = 8Hz), 6.72 (IH, d, J = 8Hz), 6.98 (IH, t, J=8Hz).
The following compounds were prepared in a similar manner to descriptions 6a and 6b.
(c) (±)-/rαπs-8-Methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo[fjquinoline
(first eluting isomer)
Η NMR (CDCl,) δ: 1.24 (IH, m), 1.60 - 2.05 (4H, m), 2.50 (2H, m), 2.59 - 3.00 (5H, m), 3.20 (IH, m), 3.76 (3H, s), 6.62 (IH, d, J = 3 Hz), 6.74 (IH, dd, J = 9, 3 Hz), 7.18 (IH, d, J = 9 Hz).
(d) (±)-cw-8-Methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo[fjquinoline
(second eluting isomer) lH NMR (CDCl,) δ:1.63 (2H, m), 1.88 (3H, m), 2.17 (IH, m), 2.92 (5H, m), 3.14 (IH, br s), 3.35 (IH, m), 3.79 (3H, s), 6.62 (IH, d, J = 3 Hz), 6.73 (IH, dd, J = 9, 3 Hz), 7.09 (lH, d, J = 9 Hz). Description 7 cis- and /rflπs-4-Methyl-l,2,3,4,4a^,6,10b-octahydrobenzo[f]quinoIine
Prepared from 2-tetralone using a procedure similar to that of Description 1 to 5 inclusive.
Mass Spectrum (API*): 202 (MH*, 100%) CMH„N requires 201.
Η NMR (CDCl,) δ: 1.15 - 2.20 (6H, m), 2.25 - 3.05 (9H, m), 7.00 - 7.35 (4H, m).
Description 8a
/rαπs-l,2,3,4,4a,5,6,10b-Octahydrobenzo[f]quinol!ne and
Description 8b cw-1^3,4,4a,5,6,10b-Octahydrobenzo[f]quinoline
1-Chloroethylchloroformate (2.01ml, 18.61mmol) was added with stirring to an ice- cooled solution of cis- and trαrt5-4-methyl-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (1.66g, 8.34mmol) in dichloromethane (60ml). The mixture was allowed to warm to room temperature and stirred for a further 2h. Diisopropylethylamine (2.2ml, 12.6mmol) was added and the mixture heated at reflux for lh. The mixture was cooled and concentrated in vacuo, dissolved in methanol and refluxed for lh. After cooling, the solvent was removed and the residue partitioned between saturated aqueous K.CO2 and dichloromethane (4x50ml). The combined organic extracts were washed with water, dried (NajSOJ and the solvent evaporated to afford an oil. Chromatography on silica using 10% methanol-ethyl acetate with 6.6ml/L 0.880 ammonia as eluent gave the trans- isomer of the title compound (260mg, 33%) as the first eluting product. Mass spectrum (API*) 188 (100%,MH*) C„H17N requires 187.
Η NMR (CDCl,) δ: 1.31 (IH, m), 1.83 (4H, m), 2.03 (IH, m), 2.55 (2H, m), 2.75 (2H, m), 2.94 (IH, m), 3.25 (IH, m), 4.3 (IH, br s), 7.00 - 7.35 (4H, m).
The cis- isomer of the title compound (170mg, 21%) was obtained as the second eluting product.
Mass spectrum (API*): 188 (MH*, 100%). C13H]7N requires 187. Η NMR (CDCl,) δ: 1.54 (2H, m), 1.76 (IH, m), 1.84 (IH, m), 1.97 (IH, m), 2.16 (IH, m), 2.43 (IH, br s), 2.83 (2H, m), 2.9 (2H, m), 2.93 (IH, m), 3.26 (IH, m), 7.00 - 7.25 (4H, m).
Description 9
3,4-Dihydro-2-hydroxynaphthalenecarboxylic acid, methyl ester
To a stirred solution of 2-tetralone (25.0g, 171mmol) in dry tetrahydrofuran (250ml) at 0°C under argon was added lithium diisopropylamide (111ml, 2M solution, 222mmol). After stirring at 0°C for lh, dimethyl carbonate was added (145ml, 1710mmol). After stirring at 0°C for 0.5h, the reaction mixture was warmed to room temperature, and then heated at reflux for 16h. The mixture was then cooled to 0°C and quenched with hydrochloric acid (IM, 450ml). The resulting mixture was extracted with ethyl acetate (3x1000ml) and the combined extracts were washed with brine (1000ml) then dried (Na.SO4) and evaporated in vacuo to afford the title compound as a dark brown oil (36.3g, 100%).
Mass spectrum (API'): 203 (M - H)' C12H12O, requires 204. ]H NMR (CDCl,) δ: 2.54 (2H, t, J = 8Hz), 2.83 (2H, t, J = 8Hz), 3.92 (3H, s), 7.03 - 7.30 (3H, m), 7.70 (IH, d, J = 9Hz), 13.32 (IH, s).
Description 10
3,4-Dihydro-2-hydroxy-3-(2-propenyl)-naphthalenecarboxyiic acid, methyl ester
To a stirred solution of 3,4-dihydro-2-hydroxynaphthalene carboxylic acid, methyl ester (36.2g, 177mmol) in dry tetrahydrofuran (440ml) at -30°C under argon was added dropwise lithium diisopropylamide (195ml, 2M solution, 390 mmol). Allyl bromide (24.3ml, 284mmol) was then added at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for lh, then treated with hydrochloric acid (5M) to pH2- 3. The resulting mixture was extracted with ethyl acetate (2x1000ml) and the combined extracts were washed with brine (1000ml), dried (Na2SO4) and evaporated in vacuo to give the title compound as a brown oil (46. lg).
Mass spectrum (API"): 243 (M - H)" C13H16O, requires 244. 'H NMR (CDCl,) δ: 2.03 (IH, m), 2.36 (IH, m), 2.62 (2H, m), 2.95 (IH, m), 3.92 (3H, s), 5.02 (2H, m), 5.76 (IH, m), 7.07 (2H, m), 7.20 (IH, m), 7.69 (IH, d, J = 9Hz), 13.41 OH, s). Description 11 3-(2-Propenyl)-2-tetraIone
A mixture of 3,4-dihydro-2-hydroxy-3-(2-propenyl)-naphthalene carboxylic acid, methyl ester (46. lg, crude), dimethyl sulphoxide (132ml), water (5ml) and lithium chloride (9.5g, 226mmol) was heated at 125°C, with stirring, under argon for 4.5h. The mixture was cooled and diluted with water (750ml) and extracted with ethyl acetate (3x1000ml). The combined extracts were washed widi water (1000ml) and brine (1000ml), dried (Na.SO4) and evaporated in vacuo to give a brown oil (35.5g). This was chromatographed on silica eluting with 10% ether-hexane to give the title compound as a brown oil (25.9g, 74%).
Mass spectrum (API"): 185 (M - H)". C„H14O requires 186.
Η NMR (CDCl,) δ: 2.14 (IH, m), 2.54 (2H, m), 2.84 (IH, m), 3.08 (IH, m), 3.60 (2H, d, J = 3Hz), 5.08 (2H, m), 5.79 (IH, m), 7.16 (4H, m)
Description 12 3-(2-Propenyl)-2-tetralone ethylene ketal
A mixture of 3-(2-propenyl)-2-tetralone (25.9g, 139mmol), trimethyl orthoformate (61.3ml, 554mmol), ethanediol (57.5ml, 1.03mol),p-toluenesulfonic acid monohydrate (0.27mg, 1.4mmol) in dichloromethane (650ml) was stirred at room temperature, under argon for 2h. Resulting mixture was partitioned between saturated aqueous sodium bicarbonate (1000ml) and dichloromethane (3x500ml). The combined organic extracts were washed with brine (500ml), dried (Na2SO4) and evaporated in vacuo to give a brown oil (34.9g). Chromatography on silica using 0-10% ether-hexane gradient elution gave the title compound as a yellow oil (20. lg, 63%).
Η NMR (CDCl,) δ: 1.91 (IH, m), 2.07 (IH, m), 2.53 (IH, m), 2.77 (IH, m), 2.99 (3H, m), 4.02 (4H, m), 5.04 (2H, m), 5.83 (IH, m), 7.08 (4H, m).
Description 13 2-Oxo-l,2,3,4-tetrahydronaphthalene-3-acetic acid, methyl ester Potassium permanganate (1.7 lg, 1 lmmol) was added to a stirred solution of sodium periodate (35.3g, 165mmol) in water (600ml) at room temperature. After 0.5h, potassium carbonate (4.58g, 33mmol) was added. After 0.25h, rerr-butanol (180ml) was added dropwise followed by 3-(2-propenyl)-2-tetralone ethylene ketal (4.2 lg, lδmmol) in rerr-butanol (180ml). After 3h, the reaction mixture was cooled to 0 °C and sodium metabisulfite added until the pink solution turned brown. The resulting mixture was diluted with water (300ml) and extracted with dichloromethane (2x500ml). The combined extracts were washed with water (500ml), and brine (500ml), then dried (NajSOJ, and the solvent evaporated in vacuo to give a yellow oil (4.64g), that was dissolved in acetonitrile (90ml) and medianolic hydrochloric acid (90ml), and stirred at room temperature under argon. After 3h, water (20ml) was added, and the mixture stirred for 2h. The resultant mixture was evaporated in vacuo and the residue was partitioned between water (50ml) and ethyl acetate (2x100ml). Combined extracts were washed with brine (100ml), dried (Na.SO4) and the solvent evaporated in vacuo to give the title compound as a yellow oil (3.62g, 91%).
Η NMR (CDCl,) δ: 2.56 (IH, m), 2.87 (2H, m), 3.05 (2H, m), 3.66 (2H, s), 3.70 (3H, s), 7.16 (4H, m).
Description 14 cis-l-Benzyl-l,3,3a,4,9,9a-hexahydro-2H-benz[f]indole-2-one
Acetic acid (12.5ml) was added to a stirred mixture of 2-oxo- 1,2,3,4- tetrahydronaphthalene-3-acetic acid methyl ester (3.62g, 17mmol), and benzylamine (7.2ml, 66mmol) in a 1:1 mixture of tetrahydrofuran and methanol (120ml) at 0°C under argon. After 0.5h, sodium cyanoborohydride (2.09g, 33mmol) was added and the resultant mixture stirred at room temperature. After 16h, aqueous 10% sodium hdyroxide was added and the solvent evaporated in vacuo. The residue was partitioned between water (100ml) and dichloromethane (2x200ml). The combined extracts were washed with water (100ml), brine (100ml), then dried (NajSO4) and evaporated in vacuo to give a brown solid (4.38g). Chromatography on silica using 0-5% methanol-ethyl acetate gradient elution afforded the title compound as a yellow solid (1.75g, 38%).
Mass spectrum (API+): 278 (MΗ+). C„H19NO requires 277. Η NMR (CDCl,) δ: 2.14 (IH, m), 2.57 (IH, m), 2.75 (5H, m), 3.86 (IH, m), 4.07 (IH, d, J = 16Hz), 4.89 (IH, d, J = 16Hz), 6.95 (IH, d, J = 2Hz), 7.15 (3H, m), 7.30 (5H, m). Description 15 α's-l-Benzyl-2,3,3a,4,9,9a-hexahydro-lH-benz[f]indole
To a stirred suspension of lithium aluminium hydride (0.96g, 25mmol) in dry tetrahydrofuran (30ml) at 0°C under argon, was added cis- 1 -benzyl- 1 ,3,3a,4,9,9a- hexahydro-2H-benz[fjindol-2-one (1.75g, 6mmol) in dry tetrahydrofuran (5ml). The resultant mixture was then heated at reflux for 6h, cooled to 0°C and, with vigorous stirring, water (1ml) was added, followed by aqueous 10% sodium hydroxide (5ml) and water (2ml). The resultant mixture was filtered and the solid residue was washed with dichloromethane (10ml). The filtrate was dried (Na.SO4) and the solvent evaporated in vacuo to give the title compound as a yellow oil (1.2g, 72%).
Mass spectrum (API+): 264 (MΗ+). C„H„N requires 263.
Η NMR (CDCl,) δ: 1.39 (IH, m), 1.90 (IH, m), 2.12 (IH, m), 2.34 - 2.63 (3H, br m), 2.78 (4H, m), 3.39 (IH, d, J = 13Hz), 3.99 (IH, d, J = 13Hz), 7.12 (4H, m), 7.26 (5H, m).
Description 16 m-2J,3a,4,9,9a-Hexahydro-lH-benz[f]indole
A mixture of as- l-benzyl-2,3,3a,4,9,9a-hexahydro-lH-benz[f]indole (1.20g, 4.6mmol) and palladium hydroxide (0.91g, 8.6mmol) in degassed methanol (90ml) was hydrogenated at 50°C and 50psi pressure for 5h. The resultant mixture was cooled and filtered through kieselguhr. The filtrate was evaporated in vacuo to give the title compound as a colourless oil (0.55g, 70%).
Mass spectrum (API+): 174 (MΗ+). C12H1SN required 173.
Η NMR (CDCl,) δ: 1.26 (IH, m), 2.00 (IH, m), 2.40 - 2.92 (8H, br m), 3.52 (IH, m), 7.14 (4H, m).
Description 17
c«-23,3a,4,9,9a-Hexahydro-5-rnethoxy-lH-benz[f]indole
Prepared from 5-methoxy-2-tetralone using a procedure similar to that of Descriptions 9 to 16 inclusive. Mass spectrum (API+): 204 (MH+). C13H17NO requires 203.
'H NMR (CDCl,) δ: 2.00 (IH, m), 2.15 - 2.95 (9H, m), 3.82 (3H, s), 6.75 (2H, m), 7.12
(IH, t, J = 8Hz).
Description 18
N-(4-Hydroxybutyl)-4-phenylbenzamide
To a stirred solution of 4-amino-l-butanol (7.34g, 82 mmol) and triethylamine (12.3ml; 8.82g, 87 mmol) in dichloromemane (100ml) at 0°C was added a solution of 4- phenylbenzoyl chloride (18.36g, 85 mmol) in dichloromethane (800ml) dropwise over 1.2 h. Resultant was stirred at 0°C for 2h then at room temperature for 18h. The resulting white solid was filtered off (15.94g) and the filtrate washed with 5% aqueous sodium hydroxide (IL). The organic phase was dried (Na2SO4) and evaporated in vacuo to give a white solid (4.96g) which was combined with the above to give the title compound (20.9g, 93%).
lH NMR (DMSO-d6)δ: 1.4 - 1.7 (4H, m), 3.26 (2H, q, J =7Hz), 3.42 (2H, q, J=7Hz), 4.43 (IH, t, J=6Hz), 7.35 - 7.55 (3H, m), 7.75 (4H, m), 7.94 (2H, d, J=9Hz), 8.52 (IH, t, J=7Hz).
Description 19 4-(4-Phenylbenzoylamino)butyraldehyde
To a mechanically-stirred solution of N-(4-hydroxybutyl)-4-phenylbenzamide (11.2g, 44.2 mmol) and triethylamine (148ml; 107.5g, 1.06 mol) in dimethyl sulfoxide (250ml) at room temperature was added, dropwise over lh, a solution of pyridine- sulfur trioxide complex (43.7g, 0.273mol) in dimethyl sulfoxide (200ml) with external cooling using a cold water bath. The mixture was stirred at room temperature for 3h, then 2M hydrochloric acid (550ml) was added slowly with ice cooling. Resultant was diluted with water (IL) then extracted with ethyl acetate (3x500ml). The combined extracts were washed with 2M hydrochloric acid (3x500ml) and water (3x500ml) then dried (Na2SO4) and evaporated in vacuo to give a semi solid (12g). Chromatography on silica gel eluting with 10-100% ethyl acetate-hexane gave the title compound as a white solid (4.72g, 42%).
1H NMR (CDC13) δ: 2.00 (2H, m), 2.65 (2H, m), 3.52 (2H, q, J=8Hz), 6.54 (IH, br m), 7.35-7.53 (3H, m), 7.54 - 7.71 (4H, m), 7.85 (2H, m), 9.83 (IH, s). Description 20
(±)-/rα/i5-2-(l-(l,2,3,4-Tetrahydro-2-(4-toluene)sulfonamido)naphthyl)malonic acid, diethyl ester
Sodium (0.33g, 14mg atoms) was added to ethanol (36ml) with stirring. After 0.6h, dimethyl malonate (2.1g, 15 mmol) was added in one portion. Resultant was stirred for 0.25h, then (±)- la,2,3,7b-tetrahydro- 1 -(4-toluene)sulfonyl-lH-naphth[ 1 ,2-b]azirine (D.A. Evans et al, J. Org. Chem, 1991 566744) (4.0g, 13 mmol) was added. The mixture was stirred at 20°C for 2.5h, then poured into water (400ml) and extracted with ethyl acetate (3 x 200ml). Combined organic extracts were dried (NajSOJ and evaporated in vacuo to give the title compound (6.2g, 100%).
Η NMR (CDCl,) δ: 1.00 and 1.27 (6H, 2 x t, J = 8 Hz), 1.77 - 2.08 (2H, m), 2.44 (3H, s), 2.82 (2H, t, J = 7 Hz), 3.44 (2H, m), 3.90 and 4.17 (4H, 2 x m), 4.44 (IH, d, J = 9 Hz), 6.92 - 7.21 (3H, m), 7.34 (2H, d, J = 9 Hz), 7.76 (2H, d, J = 9 Hz).
The following compound was prepared in a similar manner to description 20
(a) (±)-/rαπs-2-(l-(5-Methoxy-l,2,3,4-tetrahydro-2-(4- toluene)sulfonamido)naphthyl)malonic acid, diethyl ester
*H NMR (CDCl,) δ: 1.03 & 1.28 (6H, 2 x t, J = 8 Hz), 1.91 (2H, m), 2.45 (3H, s), 2.67 (2H, m), 3.39 (2H, m), 3.82 (3H, s), 3.86 - 4.02 (2H, m), 4.22 (2H, m), 4.44 (IH, d, J = 9 Hz), 6.57 (IH, d, J = 8 Hz), 6.73 (IH, d, J = 8 Hz), 7.05 (IH, tv J = 8 Hz), 7.32 (2H, d, J = 9 Hz), 7.76 (2H, d, J = 9Hz).
Description 21
(±)-f«ms-2-(l-(l,23,4-Tetrahydro-2-(4-toluene)sulfonamido)naphthyl)acetic acid
A mixture of (±)-/rα/u-2-(l-(l,2,3,4-tetrahydro-2-(4-toluene)sulfonamido)- napthyl)malonic acid, diethyl ester (6.2g, 13.5 mmol), ethanol (300ml), potassium hydroxide (20g, 0.35 mol) and water (145 ml) was heated at reflux for 3h, then concentrated in vacuo to 100ml. The mixture was acidified (pHl) with hydrochloric acid (5M), then dichloromethane (100ml) was added. Resulting solid was filtered off (4.9g), then heated with xylene (100ml) at reflux for 4h. The mixture was cooled, then evaporated in vacuo to give the title compound (3.6g, 74%).
Η NMR (DMSO-d6) δ: 1.58 (2H, m), 2.40 (3H, s), 2.46 (IH, m), 2.52 - 2.83 (3H, m), 3.09 (IH, m), 3.45 (IH, m), 6.90 - 7.12 (4H, m), 7.38 (2H, d, J = 9 Hz), 7.66 (IH, d, J = 9 Hz), 7.72 (2H, d, J = 9 Hz).
The following compound was prepared in a similar manner to description 21
(a) (±)-frαπs-2-(l-(5-Methoxy-l,23,4-tetrahydro-2-(4- toluene)sulfonamido)naphthyl)acetic acid
Η NMR (CD,OD) δ: 1.59 - 1.84 (2H, m), 2.46 (3H, s), 2.48 - 2.77 (4H, m), 3.11 (IH, m), 3.60 (IH, m), 3.79 (3H, s), 6.71 (2H, m), 7.08 (IH, t, J = 8 Hz), 7.37 (2H, d, J = 9 Hz), 7.77 (2H, d, J = 9 Hz).
Description 22
(±)-/rα/t5-2-(l-(l,23»4-Tetrahydro-2-(4-toiuene)sulfonamido)naphthyl)ethanol
To a stirred solution of (±)-rrα/w-2-(l-(l,2,3,4-tetrahydro-2-(4- toluene)sulfonamido)naphthyl)acetic acid (3.6g, 10 mmol) in dry tetrahydrofuran (110ml) was added lithium aluminium hydride (2.9g, 76 mmol), portionwise over 0.2h. Mixture was stirred at room temperature for 0.5h, then at reflux for 4h. Resultant was cooled, then water (0.5ml), followed by aqueous NaOH (10%; 2ml) and water (1.0ml) was added sequentially with ice cooling. The supernatant liquid was decanted and the precipitate extracted exhaustively with dichloromethane. The organic solutions were combined, dried (NajSO4) and evaporated in vacuo to give the title compound (2.98g, 86%) as an oil.
Mass spectrum (API*): Found 346 (MH*). C19H23NO,S requires 345.
lH NMR (CDCl,) δ: 1.45 - 2.00 (5H, m), 2.44 (3H, s), 2.76 (3H, m), 3.65 (2H, t, J = 8 Hz), 3.70 (IH, m), 6.93 - 7.17 (5H, m), 7.34 (2H, d, J = 9 Hz), 7.77 (2H, d, J = 9 Hz).
The following compound was prepared in a similar manner to description 22 (a) (±)-/rα«s-2-(l-(5-Methoxy-l,23,4-tetrahydro-2-(4- toluene)sulfonamido)naphthyl)ethanol
1H NMR (CDCl,) δ: 1.52 - 1.96 (5H, m), 2.43 (3H, s), 2.52 - 2.84 (3H, m), 3.66 (3H, m), 3.80 (3H, s), 4.66 (IH, d, J = 9 Hz), 6.65 (2H, m), 7.10 (IH, t, J = 8 Hz), 7.31 (2H, d, J = 8 Hz), 7.76 (2H, d, J = 8 Hz).
Description 23
(±)-frαn5-23,3a,4^,9b-Hexahydro-3-(4-toluene)sulfonyMH-benz[e]indole
To a mixture of (±)-rrαns-2-(l-(l,2,3,4,-tetrahydro-2-(4- toluene)sulfonamido)naphthyl)ethanol (2.9g, 8.4 mmol), triethylamine (3.8ml; 27 mmol) and dichloromethane (100ml) at 4°C under argon was added methanesulfonyl chloride (0.7ml; 9 mmol). The mixture was stirred at 20°C for 2h then partitioned between dichloromethane (50ml) and saturated aqueous NaHCO, (150ml). Organic phase was dried (NajSOJ and evaporated in vacuo to give an oil (3.7g) which was dissolved in methanol (200ml) and treated with anhydrous potassium carbonate (3.6g, 26 mmol).
Reaction mixture was stirred at 20°C for 16h then evaporated in vacuo. Residue was partitioned between water (100ml) and dichloromethane (3 x 50ml) and the combined organic extracts were dried (NajSO4) and evaporated in vacuo to give a solid (2.3g).
Chromatography on silica with 15-50% ethyl acetate - hexane gradient elution gave die title compound (1.85g, 67%) as a solid.
Mass spectrum (API*): Found 328 (MH*). C19H,,NO2S requires 327.
Η NMR (CDCl,) δ: 1.49 (IH, m), 2.02 (IH, m), 2.33 (IH, m), 2.40 (3H, s), 2.71 - 2.92 (2H, m), 2.93 - 3.17 (3H, m), 3.53 (IH, t, J = 10 Hz), 3.68 (IH, m), 6.95 (IH, d, J = 9 Hz), 7.11 (3H, m), 7.30 (2H, d, J = 9 Hz), 7.69 (2H, d, J = 9 Hz).
The following compounds were prepared in a similar manner to description 23
(a) (±)-/rαns-23,3a,4,5,9b-Hexahydro-6-methoxy-3-(4-tolueπe)suIfonyl-lH- benz[e]indole
Mass spectrum (API*): Found 358 (MH*). C20H23NO3S requires 357 (b) (4a5, 10b5Hra«s-7-Methoxy-l,2,3,4,4a,5,6,10b-octahydro-4-(4- toluene)suIfonylbenzo[f]quinoline
'H NMR (CDCl,) δ: 1.15 - 1.34 (IH, m), 1.79 - 2.08 (3H, m), 2.29 - 2.66 (3H, m), 2.44 (3H, s), 2.73 - 3.04 (4H, m), 3.79 (3H, s), 4.27 (IH, dt, J = 9 Hz), 6.67 (IH, d, J = 9 Hz), 6.85 (IH, d, J = 9 Hz), 7.13 (IH, t, J = 9 Hz), 7.30 (2H, d, J = 9 Hz), 7.73 (2H, d, J = 9 Hz).
Description 24
(±)-.nm5-233a?4,5,9b-Hexahydro-lH-benz[e]indole
A mixture of (±)-rrαΛS-2,3,3a,4,5,9b-hexahydro-3-(4-toluene)sulfonyl-lH-benz[e]indole (1.15g, 3.5 mmol), lithium aluminium hydride (0.84g, 22 mmol) and tetrahydrofuran (40ml) was heated at reflux under argon for 20h. The mixture was cooled then treated dropwise with water (1ml), aqueous NaOH (10%; 3ml) and water (1ml) with ice cooling. Dichloromethane (150ml) was added and the supernatant liquid was decanted, dried (NajSO4) and evaporated in vacuo to give the title compound (0.62g, 100%) as an oil.
Mass spectrum (API*): Found 174 (MH*) C12H15N requires 173.
Η NMR (CDCl,) δ: 1.64 - 1.87 (2H, m), 2.04 (IH, br s), 2.27 (IH, m), 2.44 (IH, m), 2.63 (IH, m), 2.79 (IH, dt, J = 11, 4 Hz), 3.04 (2H, m), 3.25 (2H, m), 7.12 (4H, s).
The following compounds were prepared in a similar manner to description 24
(a) (±)--rαπs-233a>4,5,9b-Hexahydro-6-methoxy-lH-benz[e]indole
Mass spectrum (API*): Found 204 (MH*). C13H17NO requires 203.
(b) (4aS, 10b5)-/ra/ts-7-Methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 218 (MH*). Cl4H„NO requires 217.
Η NMR (CDCl,) δ: 1.27 (IH, m), 1.58 - 1.98 (5H, m), 2.35 - 2.79 (5H, m), 2.96 (IH, dd, J = 17, 6 Hz), 3.15 (IH, m), 3.82 (3H, s), 6.70 (IH, d, J = 9 Hz), 6.93 (IH, d, J = 9 Hz), 7.16 (lH, t, J = 9 Hz). HPLC (Chiralcel OD, hexane/ethanol/diethylamine 90:10:0.1): chiral purity 93.3%
Description 25
(la5, 7b/?)-4-Methoxy-la,2,3,7b-tetrahydro-l-(4-toluene)suIfonyl-lH-naphthfl,2- bjazirine
A mixture of (5,5)-l,2-cyclohexanediamine-fc«-(2,6-dichloro)benzylidineimine (4.7g, 11 mmol), copper (I) trifluoromethylsulfonate benzene complex (2.7g, 5.4 mmol) and dichloromethane (540ml) was stirred at 25°C for lh under argon. The mixture was filtered and to the filtrate was added l,2-dihydro-8-methoxynaphthalene (5.4g, 34 mmol). The mixture was stirred at 25°C for 0.25h, men cooled to -68 °C, whereupon (N-(4- toluenesulfonyl)imino)phenyliodinane (80% pure; 17.0g, 46 mmol) was added in one portion. The mixture was stirred at -68°C to -64°C for 6h then warmed to 25°C over 16h. The reaction mixture was filtered through silica (40g) with dichloromethane elution, and the combined fractions were evaporated in vacuo. Chromatography of the residue on silica with 10 - 20% ethyl acetate-hexane gradient elution gave the title compound (7.3g, 66%) as a solid.
Stereochemistry assigned as laS, 7b/? based on analogy with aziridination of 1,2- dihydronaphthalene (Z. Li et al; J. Am. Chem. Soc. 1993, 115, 5326).
HPLC (Chiralcel OJ, hexane/ethanol 1:1): chiral purity 83.1%.
Description 26
(lS, 2S)-trα/w-5-Methoxy-l-(3-propenyl)-l,2,3,4-tetrahydro-2-(4- toluene)su!fonamidonaphthalene
To a solution of (laS, 7b/f)-4-methoxy-la,2,3,7b-tetrahydro-l-(4-toluene)sulfonyl-lH- naphth[l,2-b]azirine (as prepared in description 25) (9.8g, 30 mmol) in dry ether (600ml) under argon was added a solution of allylmagnesium bromide in ether (IM; 84ml; 84 mmol) at 10°C. Mixture was stirred at 25 °C for 17h then poured into aqueous citric acid (10%; 200ml). Resultant was extracted with ether (2 x 100ml) and the combined organic extracts were dried (NajSO4) and evaporated in vacuo. Chromatography of the residue on silica using 3:1 hexane-ethyl acetate as eluant gave a solid (11.5g), which was recrystallised twice from hexane-ethyl acetate to give the title compound (3.8g, 33%) as colourless needles.
Mass spectrum (API*): Found 372 (MH*). C.^NOjS requires 371.
'H NMR (CDCl,) δ: 1.77 (2H, m), 2.14 (IH, m), 2.32 (IH, m), 2.44 (3H, s), 2.56 (2H, m), 2.72 (IH, ddd, J = 16, 7, 3 Hz), 3.73 (IH, m), 3.81 (3H, s), 4.48 (IH, d, J = 8 Hz), 4.89 - 5.05 (2H, m), 5.57 (IH, m), 6.62 (IH, d, J = 9 Hz), 6.68 (IH, d, J = 9 Hz), 7.11 (IH, t, J = 9 Hz), 7.32 (2H, d, J = 9 Hz), 7.75 (2H, d, J = 9 Hz).
HPLC (Chiralcel OD, hexane/ethanol 9:1): chiral purity 99.5%.
Description 27
(IS, 2SHrans-3-(l-(l,2,3,4,-Tetrahydro-2-(4- toluene)sulfonamido)naphthyl)propanol
To a stirred solution of (\S, 2S)-/ra/u-5-methoxy-l-(3-propenyl)- 1,2,3,4- tetrahydro-2-(4-toluene)sulfonamidonaphthalene (3.55g, 10 mmol) in dry tetrahydrofuran (150ml) at 25°C under argon was added, dropwise over 0. lh a solution of borane in tetrahydrofuran (IM; 11ml, 11 mmol). The mixture was stirred at 25°C for 18h, then aqueous NaOH (10%; 14ml; 35 mmol) was added, followed by aqueous hydrogen peroxide (27%; 5ml; 39.5 mmol). The mixture was stirred at 25°C for 2h, then water (350ml) was added and the resulting mixture extracted with dichloromethane (3 x 120ml). Combined extracts were dried (Na,SO4) then evaporated in vacuo. Chromatography of the residue on silica with 20 - 100% ethyl acetate - hexane gradient elution gave the title compound (2.15g, 58%).
:H NMR (CDCl,) δ: 1.27 (IH, br s), 1.39 - 1.64 (4H, m), 1.65 - 1.90 (2H, m), 2.45 (3H, s), 2.55 (2H, m), 2.64 (IH, m), 3.54 (2H, m), 3.67 (IH, m), 3.81 (3H, s), 4.54 (IH, d, J = 10 Hz), 6.60 (IH, d, J = 9 Hz), 6.68 (IH, d, J = 9 Hz), 7.11 (IH, t, J = 9 Hz), 7.33 (2H, d, J = 9 Hz), 7.75 (2H, d, J = 9 Hz).
Example 1
/rαns-7-Methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a-5,6,10b- octahydrobenzo[f]quino!ine Sodium triacetoxyborohydride 0.83g, 3.9mmol) was added to a stirred mixture of trans- 7-methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (D6a, 0.57g, 2.6mmol) and 4- (4-phenylbenzoylamino)butyraldehyde (0.77g, 2.9mmol) in dichloromethane (50ml) at room temperature. After stirring for 6h, the mixture was poured onto saturated aqueous KjCO, (40ml) and extracted with dichloromethane (3x20ml). The combined organic extracts were washed with brine, dried (Na.SO4) and concentrated in vacuo to afford a white solid which was chromatographed on silica using 40-100% ethyl acetate/pentane as elution gradient. The title compound was obtained as a white solid (1 ,2g, 99%). Mass Spectrum (API*): 469 (MH*, 100%) Cj.H^Np, requires 468
'H NMR (CDCl,) δ: 1.12 - 1.32 (IH, m), 1.42 - 1.78 (7H, m), 2.13 - 2.73 (7H, m), 2.86 - 3.19 (3H, m), 3.46 - 3.57 (2H, m), 3.80 (3H, s), 6.62 - 6.80 (2H, m), 6.90 (IH, d, J = 6.6Hz), 7.10 - 7.19 (IH, m), 7.31 - 7.69 (7H, m), 8.86 (2H, d, J = 6.6Hz). The following compounds were prepared in a similar manner to Example 1
(a) (±)-/rαn5-8-Methoxy-4-(4-(4-phenyIbenzoylamino)butyl)- l,23*4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 469 (MH*). C31H,6N2O2 requires 468. Η NMR (CDCl,) δ: 1.13 (IH, m), 1.56 (IH, m), 1.66 (6H, m), 1.77 (2H, m), 2.11 (IH, dt, J = 10, 3 Hz), 2.22 (2H, m), 2.45 (IH, m), 2.55 (IH, m), 2.85 (IH, m), 2.90 (IH, m), 3.07 (IH, m), 3.53 (2H, m), 3.76 (3H, s), 6.60 (IH, d, J = 3 Hz), 6.69 (2H, m), 7.16 (IH, d, J = 9 Hz), 7.37 (IH, m), 7.45 (2H, t, J = 9 Hz), 7.59 (4H, m), 7.84 (2H, m).
(b) (±)-/rαπs-233a,4,5,9b-Hexahydro-3-(4-(4-phenylbenzoylamino)butyI)- lH-benz[e]indole
Mass spectrum (API*): Found 425 (MH*). C29H,2N2O requires 424. Η NMR (CDC13) δ: 1.53 - 1.85 (6H, m), 2.17 (3H, m), 2.35 (2H, m), 2.89 (3H, m), 3.05 (IH, dd, J = 16, 9 Hz), 3.49 (3H, m), 6.97 (IH, m), 7.04 (IH, m), 7.13 (3H, m), 7.38 (IH, m), 7.44 (2H, t, J = 9 Hz), 7.55 (2H, d, J = 9 Hz), 7.62 (2H, d, J = 9 Hz), 7.85 (2H, d, J = 9 Hz).
(c) (±)-/rα/ιs-233a,4,5,9b-Hexahydro-6-methoxy-3-(4-(4- phenylbenzoylamino)butyI-lH>benz[e]indoIe Mass spectrum (API*): Found 455 (MH*). C-JH^NjOj requires 454. Η NMR (CDCl,) δ: 1.58 - 1.86 (6H, m), 2.16 (3H, m), 2.34 (2H, m), 2.76 (IH, m), 2.90 (3H, m), 3.47 (3H, m), 3.82 (3H, s), 6.69 (2H, m), 6.83 (IH, m), 7.14 (IH, t, J = 8 Hz), 7.42 (3H, m), 7.56 (2H, d, J = 8 Hz), 7.63 (2H, d, J = 9 Hz), 7.83 (2H, d, J = 9 Hz).
(d) (4aS, 10bSHra/w-7-Methoxy-4-(4-(4-phenylbenzoylamino)butyl)- l,23,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 469 (MH*). C„H,6N2O2 requires 468.
Η NMR (CDCl,) δ: 1.25 (IH, m), 1.54 (IH, m), 1.69 (4H, m), 1.81 (2H, m), 2.04 - 2.40 (5H, m), 2.50 (2H, m), 2.65 (IH, m), 2.94 (IH, m), 3.13 (IH, m), 3.52 (2H, m), 3.81 (3H, s), 6.70 (IH, d, J = 9 Hz), 6.80 (IH, m), 6.91 (IH, d, J = 9 Hz), 7.14 (IH, t, J = 9 Hz), 7.44 (3H, m), 7.61 (4H, m), 7.86 (2H, d, J = 9 Hz).
HPLC (Chiralcel OD, hexane/ethanol/TFA 90:10:0.1): chiral purity 99.4%.
Example 2 cιs-7-Methoxy-4-(4-(4-phenylbenzoyIamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline
Sodium triacetoxyborohydride (1.5g, 6.9mmol) was added to a stirred mixture of c/s-7- methoxy-l,2,3,4,4a,5,6,10b-octahydrobenzo[fjquinoline (D6b, l.Og, 4.6mmol) and 4-(4- phenylbenzoylamino)butyraldehyde (1.4g, 5.1mmol) in dichloroethane (50ml) at room temperature. After stirring for 12h, saturated aqueous KjCO, (40ml) was added and the mixture extracted into dichloromethane (3x20ml). The combined organic extracts were washed with brine, dried (Na2SO4) and concentrated in vacuo to give a gum. Chromatography on silica, using 50-100% ethyl acetate/pentane as elution gradient, gave the title compound as a white solid (1.29g, 60%). Mass Spectrum (API*):469 (MH*, 100%) C„H,6N2O2 requires 468.
Η NMR (CDCl,) δ:1.55 - 1.93 (10H, m), 2.35 - 2.68 (4H, m), 2.81 - 3.15 (4H, m), 3.41 - 3.55 (2H, m), 3.78 (3H, s), 6.58 - 6.75 (3H, m), 7.01 - 7.12 (IH, m), 7.42 - 7.67 (7H, m), 7.82 (2H, d, J = 6.6Hz).
Example 3 /rαn5-7-Hydroxy-4-(4-(4-phenylbenzoy.amino)butyI)-l,2,3,4,4a,5,6,10b* octahydrobenzo[f]quinoline
To a stirred solution of /ra/Ly-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (El, l.lg, 2.4mol) in dichloromethane (30ml) at 0°C was added a IM solution of boron tribromide in dichloromethane (7.1ml, 7.1 mmol). The mixture was allowed to warm to room temperature and stirred for a further 72h before pouring onto crushed ice (100ml) and 0.880 ammonia (100ml) and extracting into dichloromethane (3x30ml). The combined extracts were dried (NajSO4) and evaporated in vacuo to afford a brown solid (440mg, 40%).
Mass Spectrum (API+): 455 (MH+, 100%) C-JL^O, requires 454. Η NMR (CDCl,) δ: 1.46 - 1.90 (8H, m), 2.11 - 2.72 (7H, m), 2.82 - 3.17 (4H, m), 3.45 - 3.60 (2H, m), 6.57 - 6.70 (2H, m), 6.84 - 6.91 (IH, m), 7.0 - 7.10 (IH, m), 7.34 - 7.70 (7H, m), 7.85 (2H, d, J = 6.6Hz).
The following compounds were prepared in a similar manner to example 3
(a) (±)-/rαns-8-Hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- l,23,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 455 (MH*). C30H^N2O2 requires 454.
Η NMR (CDCl,) δ: 1.22 (IH, m), 1.46 - 1.90 (9H, m), 2.19 (2H, m), 2.30 - 2.67 (3H, m), 2.75 (IH, s), 2.90 (IH, m), 3.09 (IH, m), 3.50 (2H, m), 6.56 (IH, d, J = 3 Hz), 6.66 (IH, dd, J = 9, 3 Hz), 6.75 (IH, m), 7.09 (IH, d, J = 9 Hz), 7.44 (3H, m), 7.60 (4H, m), 7.84 (2H, d, J = 9 Hz).
(b) (±)-.rαιts-233a,4,5,9b-Hexahydro-6-hydroxy-3-(4-(4- phenylbenzoylamino)butyl)-lH-benz[e]indole
Mass spectrum (API*): Found 441 (MH*). Cϊ9H,2N2O2 requires 440.
Η NMR (CDCl,) δ: 1.50 - 1.83 (8H, m), 2.11 (IH, m), 2.20 - 2.44 (3H, m), 2.61 - 2.87 (2H, m), 2.95 (2H, m), 3.48 (3H, m), 6.64 (2H, d, J = 8 Hz), 6.77 (IH, m), 7.03 (IH, t, J = 9 Hz), 7.41 (3H, m), 7.57 (2H, d, J = 8 Hz), 7.63 (2H, d, J = 9 Hz), 7.83 (2H, d, J = 9 Hz). (c) (4aS, 10b5)-ϊrαπs-7-Hydroxy-4-(4-(4-phenyIbenzoylamino)butyl)- l,23,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 455 (MH*). C^Np. requires 454. Η NMR (CDCl,) δ: 1.22 (IH, m), 1.45 - 1.85 (7H, m), 2.05 - 2.69 (7H, m), 2.90 (2H, m), 3.06 (IH, m), 3.52 (2H, m), 6.66 (2H, m), 6.85 (IH, d, J = 9 Hz), 7.04 (IH, t, J = 9 Hz), 7.42 (3H, m), 7.60 (4H, m), 7.83 (2H, d, J = 9 Hz).
Example 4 cw-7-Hydroxy-4-(4-(4-phenylbenzoylaπuno)butyl)-l,23,4,4a,5,6,10b- octahydrobenzo[f]quinoline
To a stirred solution of cis-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (E2, l.Og, 2.1mmol) in dichloromethane (50ml) at 0°C was added a IM solution of boron tribromide in dichloromethane (6.4ml, 6.4mmol). The mixture was allowed to warm to room temperature and stirred for a further 72h, then poured onto crushed ice (50ml) and 0.880 ammonia (50ml) and extracted with dichloromethane (3x30ml). The combined extracts were dried (NajSO4) and evaporated in vacuo to give a brown solid (720mg, 76%). Mass Spectrum (API*): 455 (MH+, 100%) C30H„N2O2 requires 454.
Η NMR (CDCl,) δ: 1.54 - 2.0 (9H, m), 2.35 - 2.68 (5H, m), 2.52 - 3.16 (2H, m), 3.45 - 3.55 (2H, m), 3.80 (3H, s), 6.60 - 6.77 (3H, m), 7.01 - 7.12 (IH, m), 7.32 - 7.67 (7H, m), 7.81 (2H, d, J = 6.6Hz).
Example 5 lrαn5-7-MethylsuIfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a^,6,10b- octahydrobenzo[f]quinoline hydrochloride
Methanesulfonyl chloride (0.04ml, 0.5mmol) was added to a stirred solution of trans-1- hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline(E3, 200mg, 0.4mmol) and triethylamine (0.07ml, 0.5mmol) in dichloromethane (5ml) at room temperature. The mixture was stirred for 12h and then poured onto saturated aqueous KjCO, (10ml) and extracted onto dichloromethane (3x10ml). The combined extracts were washed with brine, dried (NajSOJ and evaporated in vacuo to give an off-white solid. Chromatography on silica using 50- 100% ethyl acetate /pentane as elution gradient, afforded the free base of the title compound (200mg, 94%). The free base was treated with IM ethereal HC1 in dichloromethane to afford after evaporation the title compound as a colourless solid. Mass Spectrum (API*): 533 (MH*1 100%) C^H N.O.S requires 532 Η NMR (CDCl,) δ: 1.3 - 2.7 (9H, m), 2.7 - 3.6 (10H, m), 3.46 (3H, s), 7.28 - 7.50 (7H, m), 7.74 - 7.77 (4H, m), 7.97 (2H, d, J = 10Hz), 8.65 (IH, m), 10.85 (IH, br s).
The following compounds were prepared in a similar manner to example 5
(a) (±)-/rα«5-233a,4^,9b-Hexahydro-6-methylsuIfonyIoxy-3-(4-(4- phenylbenzoylamino)butyl)-lH-benz[e]indole
(free base)
Mass spectrum (API*): Found 519 (MH*). C^H N^S requires 518. Η NMR (CDCl,) δ: 1.54 - 1.88 (6H, m), 2.16 (3H, m), 2.42 (2H, m), 2.73 - 2.99 (3H, m), 3.08 (IH, d, J = 9 Hz), 3.19 (3H, s), 3.48 (3H, m), 6.77 (IH, m), 7.01 (IH, m), 7.15 (2H, m), 7.43 (3H, m), 7.57 (2H, d, J = 9 Hz), 7.64 (2H, d, J = 9 Hz), 7.84 (2H, d, J = 9 Hz).
(b) (4a5, 10bS)-/rβ/ts-7-Methylsulfonyloxy-4-(4-(4- phenylbenzoyiamino)butyl)-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline
Mass spectrum (API*): Found 533 (MH*). C^H N.O.S requires 532. Η NMR (CDCl,) δ: 1.25 (IH, m), 1.55 (IH, m), 1.56 - 1.89 (6H, m), 2.06 - 2.87 (3H, m), 2.88 - 2.67 (3H, m), 2.69 - 3.13 (4H, m), 3.17 (3H, s), 3.52 (2H, m), 6.60 (IH, m), 7.09 - 7.27 (3H, m), 7.44 (3H, m), 7.62 (4H, m), 7.85 (2H, d, J = 9 Hz).
Example 6 m-7-MethylsuIfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzoffjquinoline hydrochloride
Methanesulfonyl chloride (0.04ml, 0.5mmol) was added to stirred solution of αs-7- hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzoffjquinoline (E4, 200mg, 0.4mmol) and triethylamine (0.07ml, 0.5mmol) in dichloromethane (5ml) at room temperature. The mixture was stirred for 2h and then poured onto saturated aqueous KjCO, (10ml) and extracted into dichloromethane (3x10ml). The combined organic extracts were washed with brine, dried (Na2SO4) and evaporated in vacuo to give a solid which was chromatographed on silica using 50-100% ethyl acetate/pentane as elution gradient to give the free base of the title compound (156mg, 73%). The free base was treated with IM ethereal HC1 in dichloromethane to afford after evaporation the tide compound as a colourless solid.
Mass spectrum (API+): 533 (MH+ 100%) C3IH,6N2O4S requires 532.
Η NMR (CDCl,) δ: 1.55 - 2.16 (11H, m), 2.7 - 3.65 (13H, m), 7.17 - 7.52 (7H, m), 7.70
-7.78 (3H, m), 7.96 (2H, m), 10.85 (IH, m).
Example 7 frαns-4-(4-(4-Phenylbenzoylamino)butyl)-l,23>4,4a,5,6,10b- octahydrobenzo[f]quinoline
Sodium triacetoxyborohydride (340mg, l.όmmol) was added to a stirred mixture of rrfl«j-l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (D8a, 200mg, lmmol), 4-(4- phenylbenzoylamino)butyraldehyde (286mg, 01. lmmol) and acetic acid (1 drop) in 1,2- dichloroethane (10ml) at room temperature. After stirring for 16h, dichloromethane (20ml) was added and the mixture was then washed with saturated aqueous KjCO, (2x25ml) and brine (25ml). Drying (Na.SO4) and evaporation in vacuo afforded an oil which was purified by preparative TLC on Kieselgel using 10% methanol-ethyl acetate as eluent to give the title compound as a colourless solid (200mg, 46%). Mass Spectrum: found M* 438.2678; C30HMN2O requires 438.2671 Η NMR (CDC13) δ: 1.25 (IH, m), 1.58 (5H, m), 1.8 (2H, m), 2.19 (3H, m), 2.48 (2H, m), 2.64 (IH, m), 2.84 (2H, m), 3.09 (IH, m), 3.51 (2H, m), 6.68 (IH, m), 7.10 (3H, m), 7.25 (IH, d), 7.35 (IH, m), 7.45 (2H, m), 7.60 (4H, m), 7.80 (2H, d).
Example 8 c.s-4-(4-(4-Phenylbenzoylamino)buιyl)-l,23,4,4a,5,6,10b- octahydrobenzo[f]quinoline
Sodium triacetoxyborohydride (170mg, 0.8mmol) was added to a stirred mixture of cis- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline (D8b, lOOmg, 0.5mmol), 4-(4- phenylbenzoylamino)butyraldehyde (143, 0.54mmol) and acetic acid (1 drop) in 1,2- dichloroethane (8ml) at room temperature. After stirring for 16h, dichloromethane (10ml) was added and the mixture was then washed with saturated aqueous KjCO,
(2x20ml) and brine (20ml). Drying (Na.SO4) and evaporation in vacuo afforded an oil which was purified by preparative TLC on Kieselgel using 10% methanol-ethyl acetate as eluent to give the title compound as a gum (150mg, 68%). Mass spectrum: found M* 438.2679; C^rL^O requires 438.2671. Η NMR (CDCl,) δ: 1.71 (9H, m), 1.96 (IH, m), 2.47 (IH, m), 2.68 (3H, m), 2.76 (IH, m), 2.94 (2H, m), 3.2 (IH, m), 3.51 (2H, ra), 6.75 (IH, br s), 7.05 (4H, m), 7.35 (IH, m), 7.45 (2H, m), 7.60 (4H, m), 7.85 (2H, d).
Example 9 cw-233a,4,9,9a-Hexahydro-l-(4-(4-phenylbenzoylamino)butyl)-lH-benz[f]indole hydrochloride
A mixture of cw-2,3,3a,4,9,9a-hexahydro-lH-benz[f]indole (D16, 0.54g, 3.12mmol), 4- (4-phenylbenzoylamino)butyraldehyde (0.83g, 3.12mmol) and sodium triacetoxyborohydride (0.97g, 4.7mmol) in dichloroethane (120ml) was stirred at room temperature for 18h. Resulting mixture was partitioned between saturated aqueous NaHCO, (200ml) and dichloromethane (3x50ml). The combined extracts were dried (NajSO4) and evaporated in vacuo to give an oil (1.77g). Chromatography on silica eluting with 50-100%-dichloromethane-hexane and then 0-6% methanol- dichloromethane gave the free base of the title compound as a colourless solid (0.55g, 42%).
The free base was treated with IM ethereal HCl (2.6ml, 2.6mmol) in dichloromethane to afford after evaporation the title compound as a colourless solid (0.53g, 89%).
Mass spectrum (API+): 425 (MH+). 0,11,^0 requires 424.
Η NMR (DMSO-d6) δ: 1.66 (3H, m), 1.83 (2H, m), 2.30 (IH, m), 2.60 (2H, m),
2.85 (IH, m), 3.07 (3H, m), 3.24 (IH, m), 3.36 (2H, m), 3.45 (IH, m), 3.58 (IH, m), 3.68 (IH, m), 7.19 (4H, s), 7,42 (IH, m), 7.50 (2H, t, J = 8Hz), 7.74 (4H, m), 7.98 (2H, d, J = 9Hz), 8.64 (IH, m), 10.24 and 10.70 (IH, 2xbr s). Elemental Analysis: found: C, 74.26; H, 7.07; N, 5.91%;
C^Np. HCl. 0.5HP requires C, 74.10; H, 7.29; N, 5.96%.
Example 10 cis-23»3a,4,9,9a-Hexahydro-5-methoxy-l-(4-(4-phenylbenzoy!amino)butyl)-Lff- benz[f]indole hydrochloride A mixture of cιs-2,3,3a,4,9,9a-hexahydro-5-methoxy-lH-benz[f]indole (D17, 0.08g, 0.39mmol), 4-(4-phenylbenzoylamino)butyraldehyde (0.1 lg, 0.40mmol), and sodium triacetoxyborohydride (0.13g, 0.6 lmmol) in dichloroethane (20ml), was stirred at room temperature for 18h. Resulting mixture was partitioned between saturated aqueous NaΗCO3 (20ml) and dichloromethane (3x10ml). The combined extracts were dried (NajSO4) and evaporated in vacuo to give an oil. Chromatography on silica using 0-4% methanol-dichloromethane gradient elution gave the free base of the title compound as a colourless solid (0.07g, 38%). The free base was treated with IM ethereal HCl (0.31ml, 0.3mmol) in dry dichloromethane to afford after evaporation the title compound.
Mass spectrum (EI+): 454.2602 (M+); CJL^N.O, requires 454.2620. 'H NMR (DMSO-d6) δ: 1.63 (3H, m), 1.79 (2H, m), 2.31 (2H, m), 2.52 (IH, m), 3.06 (4H, m), 3.21 (IH, m), 3.35 (2H, m), 3.41 (IH, m), 3.57 (IH, m), 3.65 (IH, m), 3.77 (3H, s), 6.85 (2H, m), 7.14 (IH, t, J = 8Hz), 7.41 (IH, m), 7.48 (2H, t, J = 7Hz), 7.74 (4H, m), 7.97 (2H, d, J = 8Hz), 8.63 (IH, m), 10.13 and 10.70 (IH, 2xbr s).

Claims

Claims :
1. A compound of formula (I)
I .N Ar-Y-Ar1
Y
Formula (I)
wherein R* represents a group of formula (A) or (B):
Figure imgf000046_0001
(A) (B)
R^ represents a hydrogen atom or a Ci _4alkyl group;
R3 represents a substituent selected from: a hydrogen or halogen atom, a hydroxy, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, C1.4a.kyl, Cι_4alkoxy, arylCj^alkoxy, Cι_4alkylthio, Cι_4alkoxyCι_4alkyl, C3_6cycloalkylCι_ 4alkoxy, Cj^alkanoyl, Cι_4alkoxycarbonyl, C\ _4alkylsulphonyl, Cι_4alkylsulphonyloxy, Cι_4alkylsulphonylCι.4alkyl, arylsulphonyl, arylsulphonyloxy or arylsulphonyICι_4alkyl group, a group R3OCO(CH2)p, R3R4NCO(CH2)p or R3R^NSO2(CH2)p where each of R3 and R4 independently represents a hydrogen atom or a Cι_4alkyl group and p represents zero or an integer from 1 to 4, or a group Ar2-Z, wherein Ar2 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring and Z represents a bond, O, S , or CH2; q is 1 or 2;
T represents CH2, CH2CH2 or OCH2;
V represents CH2, O or a bond;
Ar and Ar* each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and Y represents a bond, -NHCO-, -CONH-, -CH2-, or -(CH2)mYl(CH2)n-, wherein γl represents O, S, SO2, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1; or a salt thereof.
2. A compound according to claim 1 wherein q represents 1.
3. A compound as claimed in either claim 1 or claim 2 wherein Y represents a bond.
4. A compound as claimed in any of claims 1 to 3 wherein Ar and Ar* both represent unsubstituted phenyl.
5. A compound of formula (I) which is: rra/w-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[fjquinoline; cw-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f] quinoline; /rα/w-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)- 1,2,3,4 ,4a,5,6, 10b- octahydrobenzo[f]quinoline; cw-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; rrαns-7-methylsulfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzo[f]quinoline; c«-7-methylsulfonyloxy-4-(4-(4-phenylbenzoylamino)butyl)- 1 ,2,3,4,4a,5,6, 10b- octahydrobenzo[f]quinoline; rra/ts-4-(4-(4-phenylbenzoylarnino)butyl)- 1 ,2,3,4 ,4a,5,6, 10b- octahydrobenzo[f]quinoline; cw-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b-octahydrobenzo[fJquinoline; cw-2,3,3a,4,9,9a-hexahydro- l-(4-(4-phenylbenzoylamino)butyl)- lH-benz[f]indole; c«-2,3,3a,4,9,9a-hexahydro-5-methoxy-l-(4-(4-phenylbenzoylamino)butyl)-lH- benz[f]indole; rrαΛS-8-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; tra/w-2,3,3a,4,5,9b-hexahydro-3-(4-(4-phenylbenzoylamino)butyl)-lH-benz[e]indole; frαra-2,3,3a,4,5,9b-hexahydro-6-methoxy-3-(4-(4-phenylbenzoylamino)butyl-lH- benz[e]indole; (4a5, 10b5)-rra/i5-7-methoxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[fjquinoline; rrαns-8-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; ιrflΛS-2,3,3a,4,5,9b-hexahydro-6-hydroxy-3-(4-(4-phenylbenzoylamino)butyl)-lH- benz[e]indole; (4aS, 10b5)-rrα/t5-7-hydroxy-4-(4-(4-phenylbenzoylamino)butyl)-l,2,3,4,4a,5,6,10b- octahydrobenzo[f]quinoline; rrα/tf-2,3,3a,4,5,9b-hexahyo!ro-6-methylsulfonyloxy-3-(4-(4-phenylbenzoylamino)butyl)- lH-benz[e]indole;
(4aS, 10b5)-rrαΛS-7-medιylsulfonyloxy-4-(4-(4-phenyIbenzoylamino)butyl)- l,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline;
or a salt thereof.
6. A process for preparing a compound of formula (I) as defined in any of claims 1 to 5 which process comprises:
(a) reacting a compound of formula (II):
RlH Formula (II)
wherein RMs as hereinbefore defined; with a compound of formula (III):
Figure imgf000048_0001
Formula (III)
wherein R2, Y, Ar and Ar* are as hereinbefore defined;
(b) reaction of a compound of formula (IV):
Figure imgf000049_0001
Formula (IV)
wherein R* and R2 are as hereinbefore defined; with a compound of formula (V):
Ari-Y-ArCOX
Formula (V)
wherein Y, Ar and Ar* are as hereinbefore defined and X is a halogen atom or the residue of an activated ester; (c) to prepare a compound of formula (I) where Y is a bond, reaction of a compound of formula (VI):
Figure imgf000049_0002
Formula (VI)
wherein R*, R2 and Ar are as hereinbefore defined, and W is a halogen atom or a trifluoromethylsulphonyloxy group, or W is a group M selected from a boron derivative or a metal function; with a compound: Ari-W1 wherein W* is a halogen atom or a trifluoromethylsulphonyloxy group when W is a group M, or W* is a group M when W is a halogen atom or a trifluoromethylsulphonyloxy group.
(d) interconversion of one compound of formula (I) to a different compound of formula (I); and optionally thereafter forming a salt of formula (I).
7. A pharmaceutical composition comprising a compound of formula (I) as claimed in any of claims 1 to 5 or a physiologically acceptable salt thereof and a physiologically acceptable carrier therefor.
8. The use of a compound of formula (I) as claimed in any of claims 1 to 5 or a physiologically acceptable salt thereof in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.
9. Use acording to claim 8 wherein the dopamine receptor is a dopamine D3 receptor.
10. Use according to claim 8 or claim 9 wherein a dopamine antagonist is required.
11. Use according to any of claims 8 to 10 wherein the condition is a psychotic condition.
12. A method of treating a condition which requires modulation of a dopamine receptor which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 or a physiologically acceptable salt uiereof.
PCT/EP1997/002985 1996-06-11 1997-06-06 Tricyclic amine derivatives WO1997047602A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/202,335 US6080752A (en) 1996-06-11 1997-06-06 Tricyclic amine derivatives
EP97928161A EP0906284A1 (en) 1996-06-11 1997-06-06 Tricyclic amine derivatives
JP10501180A JP2000511917A (en) 1996-06-11 1997-06-06 Tricyclic amine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9612153.8 1996-06-11
GBGB9612153.8A GB9612153D0 (en) 1996-06-11 1996-06-11 Compounds

Publications (1)

Publication Number Publication Date
WO1997047602A1 true WO1997047602A1 (en) 1997-12-18

Family

ID=10795076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002985 WO1997047602A1 (en) 1996-06-11 1997-06-06 Tricyclic amine derivatives

Country Status (5)

Country Link
US (1) US6080752A (en)
EP (1) EP0906284A1 (en)
JP (1) JP2000511917A (en)
GB (1) GB9612153D0 (en)
WO (1) WO1997047602A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007986A1 (en) * 1998-07-31 2000-02-17 Boehringer Ingelheim Pharma Kg Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
US6579892B1 (en) 1999-01-12 2003-06-17 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
WO2011087713A2 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764890B1 (en) * 1997-06-24 1999-08-27 Adir NOVEL CHROMENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6784200B2 (en) * 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
JP7361584B2 (en) * 2018-12-19 2023-10-16 高砂香料工業株式会社 Method for producing amines by reduction of amides

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106486A2 (en) * 1982-09-07 1984-04-25 Eli Lilly And Company Improvements in or relating to novel octahydrobenz(f)isoquinolines
EP0127597A1 (en) * 1983-04-27 1984-12-05 Per Arvid Emil Carlsson Octahydrobenzo(f)quinoline derivatives
WO1991000856A2 (en) * 1989-07-13 1991-01-24 The Upjohn Company (1,2n) and (3,2n)-carbocyclic-2-amino tetralin derivatives
EP0410535A2 (en) * 1989-07-28 1991-01-30 Merck Sharp & Dohme Ltd. Octahydrobenzisoquinoline derivatives as antipsychotic agents
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
WO1992021654A2 (en) * 1991-05-20 1992-12-10 The Upjohn Company Carboxamido-(3,2n)-carbocyclic-2-aminotetralin derivatives
EP0548664A1 (en) * 1991-12-20 1993-06-30 F. Hoffmann-La Roche Ag 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives
WO1995014006A1 (en) * 1993-11-19 1995-05-26 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS
FR2729145A1 (en) * 1995-01-06 1996-07-12 Smithkline Beecham Lab New heterocyclic amine derivs.
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59215640A (en) * 1983-05-23 1984-12-05 Hitachi Ltd Electron gun for color picture tube

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106486A2 (en) * 1982-09-07 1984-04-25 Eli Lilly And Company Improvements in or relating to novel octahydrobenz(f)isoquinolines
EP0127597A1 (en) * 1983-04-27 1984-12-05 Per Arvid Emil Carlsson Octahydrobenzo(f)quinoline derivatives
WO1991000856A2 (en) * 1989-07-13 1991-01-24 The Upjohn Company (1,2n) and (3,2n)-carbocyclic-2-amino tetralin derivatives
EP0410535A2 (en) * 1989-07-28 1991-01-30 Merck Sharp & Dohme Ltd. Octahydrobenzisoquinoline derivatives as antipsychotic agents
WO1992020655A1 (en) * 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
WO1992021654A2 (en) * 1991-05-20 1992-12-10 The Upjohn Company Carboxamido-(3,2n)-carbocyclic-2-aminotetralin derivatives
EP0548664A1 (en) * 1991-12-20 1993-06-30 F. Hoffmann-La Roche Ag 2,3,3a-5,9b-hexahydro-1H-benzo(e)indole derivatives
WO1995014006A1 (en) * 1993-11-19 1995-05-26 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS
FR2729145A1 (en) * 1995-01-06 1996-07-12 Smithkline Beecham Lab New heterocyclic amine derivs.
WO1997017326A1 (en) * 1995-11-10 1997-05-15 Novo Nordisk A/S Enantiomers of cis-benz[e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. SONESSON ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 37, 1994, WASHINGTON US, pages 2725 - 2753, XP002040431 *
C.-H. LIN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, 1993, WASHINGTON US, pages 1053 - 1068, XP002040432 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
WO2000007986A1 (en) * 1998-07-31 2000-02-17 Boehringer Ingelheim Pharma Kg Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments
JP2002522418A (en) * 1998-07-31 2002-07-23 ベーリンガー インゲルハイム ファルマ コマンディトゲゼルシャフト Novel 2,3,3a, 4,9,9a-hexahydro-8-hydroxy-1H-benz [f] indole, a process for their preparation and their use as medicaments
EA003370B1 (en) * 1998-07-31 2003-04-24 Бёрингер Ингельхайм Фарма Кг Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a methods for the production thereof, and their use as medicaments
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6602867B1 (en) 1999-01-12 2003-08-05 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
US6583166B1 (en) 1999-01-12 2003-06-24 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
US6579892B1 (en) 1999-01-12 2003-06-17 Abbott Laboratories Triazole compounds with dopamine-D3-receptor affinity
BG65105B1 (en) * 1999-01-12 2007-02-28 Basf Aktiengesellschaft Triazole compounds with dopamine-d3-receptor affinity
BG65086B1 (en) * 1999-01-12 2007-02-28 Basf Aktiengesellschaft Triazole compounds with dopamine-d3-receptor affinity
WO2011087713A2 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions
WO2011087713A3 (en) * 2009-12-22 2011-10-27 Cephalon, Inc. Substituted hexahydrochromeno [3, 4 - b] pyrroles with affinity for the serotonin receptor (5-ht) family
EP2792678A1 (en) 2009-12-22 2014-10-22 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions

Also Published As

Publication number Publication date
GB9612153D0 (en) 1996-08-14
EP0906284A1 (en) 1999-04-07
JP2000511917A (en) 2000-09-12
US6080752A (en) 2000-06-27

Similar Documents

Publication Publication Date Title
US6008219A (en) Bicyclic amine derivatives and their use as anti-psychotic agents
US4612316A (en) Tricyclic amines with central dopaminergic activity
EP0674621B1 (en) Enantiomers of carbazole derivatives as 5-ht1-like agonists
EP0906284A1 (en) Tricyclic amine derivatives
WO1998051671A1 (en) Substituted tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
EP0586525B1 (en) Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US6358974B1 (en) Isoquinoline derivatives
US20030158222A1 (en) 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents)
JPH04507408A (en) (1,2N) and (3,2N)-carbocyclic-2-aminotetralin derivatives
CZ291323B6 (en) Azaspirodecane derivatives, process of their preparation and medicament based thereon
US5616603A (en) Enantiomers of carbazole derivatives as 5-HT1 -like agonists
CA2179634C (en) 4-arylisoindole analgesics
US5618948A (en) Process for preparing an enantiomer of a carbazole derivative
CA2039320A1 (en) Biogenic amine uptake inhibitors
US6414154B1 (en) Tetraisoquinoline derivatives as modulators of dopamine D3 receptors
EP1086095B1 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
CA2118920A1 (en) Benzo-isoquinoline derivatives and analogs and their use in therapeutics
EP0539209A1 (en) Benzo-isoquinoline derivatives and analogs and their use in therapeutics
US5917054A (en) Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US6855717B2 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
CA1266675A (en) 6-oxygenated-1,3,4,5-tetrahydrobenz(cd)indol-4-amines
NZ299232A (en) (+)-6-carboxamido-3-n-ethylamino-1,2,3,4- tetrahydrocarbazoles; medicaments thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997928161

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09202335

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997928161

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997928161

Country of ref document: EP